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Abstract
Childhood obesity and its associated health consequences, such as type 2 diabetes mellitus,
have dramatically increased over the past 30 years, with the greatest rise in African-American
female children and adolescents. Although current prevention efforts show promising results,
recent genetic findings may soon expand treatment strategies to include new medications and gene
therapies specifically designed to prevent the development of obesity and type 2 diabetes in
children. However, little is known about the acceptability of these interventions. The primary aim
of this study was to examine the hypothetical impact of genetic knowledge on treatment
acceptability in the prevention of childhood obesity and type 2 diabetes. This study compared the
effects of ethnicity (African-American, Caucasian), maternal weight status (Normal,
Overweight/Obese), and genetic predisposition to obesity or diabetes on mothers’ perceptions of
six interventions for their children: no treatment, dietary change, physical activity, medication,
family lifestyle change, and gene therapy. Ethnicity and parent weight have both been found to
influence outcomes in weight-loss programs. Thus, the design of the study was a 2 (ethnicity) x 2
(weight status) x 2 (type of problem) x 6 (treatment) multi-factorial design. Participants were 146
females whose children were between the ages of 2 and 17 years. Using the Treatment Evaluation
Inventory-short form (Kelley, Heffer, Gresham, & Elliott, 1989), mothers rated the acceptability
of the six strategies for their children. General findings suggest that mothers viewed the behavioral
and lifestyle strategies as acceptable prevention interventions, whereas they considered the
medical strategies (and no treatment at all) as unacceptable alternatives. Heightened disease risk
of type 2 diabetes increased acceptability for all forms of treatment, specifically medication.
However, gene therapy was generally ranked as more acceptable than medication, suggesting that
mothers might consider this treatment option instead of medication when more intrusive strategies
v

are preferred. Overall, these findings provide a basis for future investigations of the impact of
genetic knowledge on treatment and prevention choices. These findings are further discussed
within the framework of future marketing strategies directed at potential consumers.

vi

Introduction
People will soon have the possibility to learn about their genetic susceptibility to specific
diseases and chronic medical conditions. Genetic testing is being increasingly sought by
individuals who wish to learn their predisposition to later-onset illness (Patterson, Eaton, &
Potter, 1999) due to the recent advances in genetics research, specifically, the findings of the
Human Genome Project (HGP). Begun in 1990, this international research program recently
completed its primary goal of sequencing the entire human genome. Since completing the ‘map’,
investigators have been searching for the functions of the genes, attempting to relate specific
phenotypes to regions of the genome.
However, the recent genetic findings have outpaced our ability to respond to the
implications of the resulting data. Individuals will have to cope with information about risk factors
in their genes, factors that predispose them to developing conditions in association with specific
environmental variables. Armed with this genetic information, they will have to choose among
various treatments or preventive interventions for themselves and for their children. This
information may affect their treatment and prevention choices. Bio-ethicists are questioning the
impact of genetic knowledge: Will parents treat a child at increased risk for disease differently
than an unaffected child? How does genetic information affect planning for the future? (Ridley,
1999). Medical researchers are predicting the development of new medications and procedures
tailored to specific genotypes. Already, media broadcasts and publications are informing the
public that human cloning and genetic engineering will soon be possible in order to create
‘designer’ children (e.g., Rowland, 2000). Experimental gene therapy has been initiated, with both
favorable and tragic results. Debates are raging both for and against the possibilities, for and
against the acceptability of these procedures.
1

Despite these worries, the HGP provides a new direction for prevention efforts in chronic
conditions, such as obesity and type 2 diabetes. Childhood obesity, dramatically increasing in
prevalence, is strongly associated with adult obesity as well as a multitude of serious health
consequences, including type 2 diabetes (T2DM). The recent surge in research on the prevention
of obesity and the creation of ‘obesitology’ clinics is due in part to the potential for identification
of genes for obesity (Epstein, 1999; Sorensen & Stunkard, 1993). Because obesity in adulthood
can be prevented by treatment in childhood/early adolescence, early identification of ‘geneticallypredisposed’ individuals is critical for early intervention efforts. Genetic susceptibility has
traditionally been defined by having at least one obese parent (Lake, Power, & Cole, 1997);
however, a more specific test may soon be available. Although the test will yield only
probabilities, some parents may not want to know this information or may feel uncomfortable
about making a “prevention decision.” This poses an ethical problem that needs to be addressed –
the role of the psychologist is to minimize harm to others while respecting their rights and dignity
(American Psychological Association, 1992).
Knowledge of a genetic predisposition to obesity and T2DM may affect the acceptability
of the treatment choices. There are certain strategies likely to be tested as prevention approaches:
(a) dietary change; (b) physical activity; (c) medication; (d) gene therapy; and (e) family lifestyle
change. However, we do not know whether parents will prefer (i.e., find acceptable) one
approach to another, regardless of the efficacy of the approaches. Different parental
characteristics (e.g., ethnicity, weight concerns) may influence choices of acceptable and
unacceptable interventions. A child’s probability of becoming obese or developing T2DM could
sway prevention decisions. For example, a parent with a child who has a high probability of
becoming obese might opt for an intrusive intervention (e.g., gene therapy) over traditional
2

treatments that alter environmental and behavioral variables (e.g., dietary intake or physical
activity). As an illustration, Milner and colleagues (1998) found that the hypothetical availability
of “curative gene therapy” significantly increased the desire for prenatal testing of obesity.
The present study will be the first to address the hypothetical impact of genetic knowledge
on treatment acceptability in the prevention of obesity and T2DM. To date, little is known about
the acceptability of prevention efforts in response to genetic testing. Therefore, the following
sections will provide a rationale for prevention as well as identify factors that affect the success of
prevention efforts. A brief discussion of treatment acceptability is necessary to identify other
factors that could influence the perceived acceptability of interventions.

3

Review of the Literature
Rationale for the Prevention of Obesity
Prevalence. The increasing prevalence, numerous health and psychosocial risks, and
exorbitant economic costs of obesity – approximately $100 billion per year in the US
(Quesenberry, Caan, & Jacobson, 1998; Wolf & Colditz, 1998) – clearly justify the need for
prevention efforts. Data from successive national surveys conducted from 1960 through 1999
indicate a dramatic increase in the prevalence of obesity in children and adolescents, with the
largest increase occurring during the most recent surveys (Flegal, Carroll, Kuczmarski, &
Johnson, 1998; Flegal, Ogden, Wei, Kuczmarski, & Johnson, 2001; National Center for Health
Statistics, 2001; Popkin & Udry, 1998; Troiano & Flegal, 1998). From 1963 to 1965,
approximately 4% of children and adolescents were considered obese1, compared to 11% in 1988
to 1994 and 13% in 1999. An additional 14% were considered ‘at-risk’ for becoming overweight
(Troiano & Flegal, 1998). The prevalence of obesity in African-American (AA) female children
(16.4%) and Mexican American female children (14.3%) was higher than that of Caucasian
female children (9.1%; Troiano & Flegal, 1998). This pattern continues into adolescence and
adulthood; the prevalence of obesity was higher for AA (37.4%) and Mexican American women
(34.2%) than Caucasian women (22.4%), indicating that obesity is disproportionately higher
among minority women (Gannon, DiPietro, & Poehlman, 2000).
Associated Health Risks. The increasing prevalence of obesity in children and adolescents
is alarming due to the associated health risks. Obesity that begins early in life tends to persist into
adulthood, with an increased risk of obesity-related morbidity later in life regardless of adult
weight (Calle, Thun, Petreli, Rodriguez, & Heath, 1999; Dietz, 1998; Goran, Reynolds, &
Lindquist, 1999; Guo, Roche, Chumblea, Gardner, & Siervogel, 1994). Obesity is closely related
4

to an increased risk of T2DM, cardiovascular disease (CVD), osteoarthritis, respiratory
dysfunction, and some forms of cancer (Calle et al., 1999; Flegal et al., 1998; Goran et al., 1999;
Kuczmarski et al., 1993). Data indicate that the health risks of T2DM and CVD are increasing in
children and adolescents.
Until recently, T2DM was considered rare in the pediatric population, historically
accounting for approximately 2% of all newly diagnosed cases (Pinhas-Hamiel & Zietler, 1998).
However, the incidence of T2DM has increased 10-fold in children in recent years, a finding most
apparent among obese children (Pinhas-Hamiel et al., 1996). T2DM is now accounting for almost
40% of new-onset cases of DM among adolescents (Pinhas-Hamiel & Zeitler, 1998), with a
decreasing age of onset (Young, Dean, Flett, & Wood-Steiman, 2000). T2DM occurs at a higher
rate among female than male children/adolescents (ratio = 1.7:1) and concentrates in some groups
(i.e., Hispanics, AA) more than others (Pinhas-Hamiel & Zeitler, 1998). The finding that T2DM is
disproportionately higher among black and Hispanic adult females than non-Hispanic whites
parallels that of obesity prevalence. The pathogenesis and associated risks of T2DM are described
more fully in the following section.
National and community studies of children and adolescents also indicate a marked
increase in CVD risk factors, such as high blood pressure and elevated cholesterol levels, most
notably in black female children and adolescents (Hubert, Feinleib, McNamara, & Castelli, 1983;
NGHS Research Group, 1992; Morrison, James, Sprecher, Khoury, & Daniels, 1999; Rabkin,
Matthewson, & Hsu, 1977; Williams et al., 1992). These increased CVD risk and ethnic
differences continue into adulthood, especially in AA women, corresponding with obesity trends
(Wattigney, Webber, Srinivasan, & Berenson, 1995; Kumanyika, 1994; Morrison et al., 1994;
NGHS, 1992). Unfortunately, the cumulative effects of obesity, high blood pressure, and high
5

cholesterol levels may produce physiologic changes that are not fully repairable at a later date by
changes in diet and weight (Jeffery, 1988; Power, Lake, & Cole, 1997). New data in adults
suggest that a balanced weight loss diet can improve CVD risk factors in adults who already
demonstrate cardiovascular disease (McCarron & Reusser, 2001). Weight loss in childhood may
reduce the risk of adult obesity and has been related to improvement in CVD risk factors (Epstein,
Kuller, Wing, Valsoki, & McCurley, 1989), suggesting the importance of early intervention.
Quality of Life. The consequences of childhood and adolescent obesity extend beyond
health risks. Studies comparing obese and nonobese individuals have generally failed to find
consistent differences in global aspects of psychological functioning, such as depression and
anxiety. Overall, it appears that among non-clinical samples of obese individuals, rates of
diagnosable psychopathology are no greater than among non-obese groups (Stunkard & Wadden,
1992; Wadden & Stunkard, 1985; Wadden, Womble, Stunkard, & Anderson, 2002; Williamson &
O’Neil, in press). However, some domains of function are negatively affected by overweight
status and particular subsamples of overweight individuals (e.g., obese adolescents) are at
increased risk for psychosocial distress, including body image disturbance, peer relationship
difficulties, negative self-perceptions, and lower self-esteem (Friedman & Brownell, 1995; Kimm,
Sweeney, Janovsky, & MacMillan, 1991; Strauss, 2000; Striegel-Moore et al., 2000). Obesity in
adolescence has been found to predict (in adulthood) lower rates of marriage, and for females,
lower educational achievement and income and higher rates of poverty in adulthood (Gortmaker,
Must, Perrin, Sobol, & Dietz, 1993; Sargent & Blanchflower, 1994; Stunkard & Sorensen, 1993).
These results were independent of baseline education, self-esteem, and household income,
suggesting that early obesity in females may actually be an important determinant of later
socioeconomic status (Gortmaker et al., 1993).
6

Long-Term Weight Loss. Researchers of obesity have debated the efficacy of weight loss
programs for adults. Although weight control research has dramatically improved short-term
treatment efficacy in adults, it has been less successful in improving long-term success. Several
critics question the usefulness of dieting, citing evidence that most individuals regain their lost
weight within five years (Garner & Wooley, 1991; Goodrick & Foreyt, 1991). Other researchers
cite long-term efficacy and continue to support the treatment of overweight adults (Brownell &
Rodin, 1994). Most reports of successful long-term weight loss, however, are associated with
longer duration of treatment (Diabetes Prevention Program [DPP] Research Group, 2002;
Goldfield, Raynor, & Epstein, 2002; Jeffery et al., 2000) and/or in a pediatric population (Jeffery
et al., 2000). In light of evidence that obesity tends to track into adulthood, the inability to
achieve and maintain weight losses in adulthood is alarming and provides further rationale for
prevention efforts.
Type 2 Diabetes as a Consequence of Obesity
In most cases, T2DM should itself be considered a complication of obesity (Pinhas-Heimel
& Zeitler, 2000). As such, the dramatically increasing prevalence of T2DM in children and
adolescents calls for further obesity prevention efforts (e.g., Pinhas-Heimel & Zeitler, 2000).
Diabetes mellitus (DM) is a name given to a group of metabolic disorders arising from defects in
insulin secretion, insulin action, or both. Type 1 DM is characterized by absolute insulin deficiency
as a result of autoimmune destruction of the pancreatic β-cell. Type 2 DM describes peripheral
insulin resistance and relative (rather than absolute) insulin deficiency.
Those considered as at-risk for developing T2DM tend to exhibit a constellation of risk
factors: abdominal obesity, hypertension, dyslipidemia, and insulin resistance (Reaven, 1988). This
metabolic syndrome, also known as Syndrome X or Insulin Resistance Syndrome (IRS), appears
7

to be genetically based, as shown in twin studies (Newman et al., 1987; Medici, Hawa, Ianari,
Pyke, & Leslie, 1999; Poulsen, Ohm Kyvik, Vaag, & Beck-Nielsen, 1999; Poulsen, Vaag, &
Beck-Nielsen, 1999; Poulsen, Vaag, Kyvik, & Beck-Nielsen, 2001) and gene searches (e.g.,
Elbein, 1997; Klannemark et al., 1998; Plum et al., 2000). However, researchers admit that the
influence of genetic factors in the expression of T2DM is unclear. They conclude that although a
genetic predisposition for T2DM exists, modifiable risk factors such as obesity, sedentary lifestyle,
and increased saturated fat intake are important determinants in the expression of T2DM (Glaser,
1997; Helmrich, Ragland, Leung, & Paffenbarger, 1995; Kitagawa, Owada, Urakami, &
Yamauchi, 1998; Pinhas-Heimel et al., 1999; Knowler, Pettitt, Saad, & Bennett, 1990).
Obesity especially seems to precipitate overt diabetes in ‘genetically’ prone individuals.
The primary defect in T2DM is a peripheral insulin resistance. Obesity and sedentary lifestyle are
associated with reduced insulin sensitivity and the risk factors identified in the IRS, which are
occurring in children as young as five years old (Burke, Hale, Hazuda, & Stern, 1999; Danadian
et al., 1999; Ferrannini & Camastra, 1998; Gower, Nagy, & Goran, 1999; Srinivasan, Myers, &
Berenson, 1999; Young-Hyman, De Luca, Schlundt, Counts, & Herman, 2001). Initially, there is
a compensatory increase in insulin secretion, as indicated by elevated fasting insulin levels.
However, pancreatic β -cell function eventually declines and insulin secretion decreases. The
consequent hyperglycemia (“high blood sugar”) further worsens peripheral insulin resistance and
β -cell function.
In children, the average age of onset of T2DM is 12 to 14 years (Glaser, 1997; PinhasHeimel & Zeitler, 1996), an age which coincides with the increase in insulin resistance known to
occur during normal pubertal development (Amiel, Sherwin, & Simonson, 1986). This resistance
likely compounds the problem of impaired glucose tolerance in populations at risk for T2DM
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(Callahan & Mansfield, 2000). Ethnicities with higher rates of T2DM among adults also exhibit
higher rates of glucose intolerance/insulin resistance and T2DM among children and adolescents.
For example, AA children with normal glucose levels have been shown to exhibit increased fasting
insulin levels and decreased insulin sensitivity when compared to age- and weight-matched white
children, indicating an uneven baseline that starts in childhood (Arslanian, 1998; Arslanian &
Suprasongsin, 1996; Glaser, 1997; Goran, 2001; Libman & Arslanian, 1999). These findings, in
conjunction with the finding that childhood obesity predicts the development of IRS in adulthood
(Srinivasan, Myers, & Berenson, 2002), underscore the importance of weight control early in life.
Associated Health Risks. The long-term consequences of T2DM in children and
adolescents are not well studied. In adults, sustained hyperglycemia (resulting from poor glucose
control) accelerates the micro- and macrovascular disease leading to neuropathy, retinopathy,
nephropathy, and CVD (Expert Committee, 1999). Disease duration and the level of
hyperglycemia are associated with the development of these complications (Klein, 1995;
Uusitupa, Niskanen, Siitonen, Voutilainen, & Pyörälä, 1993). Correspondingly, an earlier age of
onset will lead to an earlier onset of diabetic complications (Fagot-Campagna et al., 2000). For
example, adherence to the complicated management of T2DM in childhood is extremely low,
resulting in lengthy periods of hyperglycemia. Poor glucose control during the teenage years and
the long duration of T2DM may predispose to an early onset of complications (Fagot-Campagna
et al., 2000). These findings highlight the critical importance of early identification and
intervention of childhood obesity in populations at high risk for T2DM to avert long-term health
consequences (Pinhas-Heimel & Zeitler, 2000; Young et al., 2000).
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Brief Review of Obesity Prevention Studies
The development of obesity is not completely understood (Ravussin & Swinburn, 1992;
Rosenbaum, Leibel, & Hirsch, 1997). In most cases, obesity probably results from an interaction
between genetic factors and environmental conditions – inherited metabolic characteristics
combined with unfavorable environmental conditions (e.g., minimal physical demands) can lead to
the development of obesity. To date, genome-wide scans have identified over 250 genes, markers,
and chromosomal regions that are associated or linked with human obesity phenotypes (Pérusse et
al., 2001), several of which overlap with those linked to T2DM (Elbein, 1997). Studies of
adoptees and twins reared apart indicate that approximately 66% of the variability in body size
and body composition can be attributed to genetic factors (Allison et al., 1996; Allison, Matz,
Pietrobelli, Zannolli, & Faith, 2001; Price & Gottesman, 1991; Stunkard, Harris, Pedersen, &
McClearn, 1990). Genetic predisposition to obesity has been further demarcated. Evidence from
prospective studies attributes 12% of the variability in body size to metabolism, 10% to
spontaneous physical activity, 5% to fat oxidation, and 40% to the regulation of food intake
and/or intentional activity (Ravussin & Bogardus, 2000). The remaining 33% of the variability in
body size is attributed to environmental factors.
Prevention research targets the modifiable environmental factors that may increase the risk
of obesity (e.g., diet, physical activity, parental/family support) in ‘genetically-predisposed’
individuals. Most studies have focused on treatment of childhood obesity, based on the rationale
that treating obesity in children may prevent or delay adult obesity (Schmitz & Jeffery, 2002).
Although adult treatment focuses on weight loss, childhood treatment usually targets the
prevention of weight gain. Because lean body mass increases as children age, keeping fat mass
constant will result in a normalization of body weight (Rees, 1990). Therefore, the major goal of
10

prevention efforts in children is to establish lifelong behavior patterns that reduce the likelihood of
weight gain and the development of obesity.
General Short-term and Long-term Findings. Short-term efficacy up to 12 months has
been established for behavioral interventions with childhood obesity (ages 6 to 12 years), with an
average stable reduction in percent overweight of 25% across studies (Epstein, Wing, Steranchak,
Dickson, & Michelson, 1980; Israel, Stolmaker, & Adrian, 1985; Goldfield et al., 2002). Percent
overweight in untreated comparison groups tended to remain the same or increase in the shortterm. Maintenance of treatment efficacy has been documented in a series of studies conducted by
Epstein and colleagues. Children treated in four studies of family-based behavioral interventions
were assessed at 5- and 10-year periods. At 10-year follow-up, a significant proportion
(approximately 30%) of children across the four treatment interventions had achieved nonobese
status (Epstein, Valoski, Wing, & McCurley, 1994). Weight loss studies in adolescents (ages 12
to 18 years), however, report more modest effects, with a rate of weight regain similar to that
reported by adult studies (Jelalian & Saelens, 1999). Treatment effects appear to be more stable in
children than in adolescents; however, the literature targeting adolescents is not as well developed
as that for children, making it difficult to draw conclusions about treatment efficacy (Jelalian &
Saelens, 1999).
Lifestyle Change. A second generation of studies has attempted to identify the specific
treatment modalities that lead to short-term and long-term weight loss (Jelalian & Saelens, 1999).
Most studies asserting successful treatment outcome describe behavior modification interventions
(e.g., Epstein et al., 1980). Treatment is typically conducted in weekly groups that receive
nutrition and exercise education. Training in behavioral techniques usually includes contingency
management, self-monitoring of diet and physical activity, stimulus control, and reinforcement of
11

behavior change. Behaviors targeted during treatment may be changes in eating behavior,
selection of low calorie meals, and parent use of praise. Generally, behavioral treatments targeting
dietary intake and physical activity are superior to wait-list control (Aragona, Cassady, &
Drabman, 1975; Epstein, Wing, Koeske, & Valoski, 1984) and to nutrition education alone
(Epstein et al., 1980) in achieving short-term weight loss in children. Treatment conditions with
superior long-term outcomes target a combination of dietary change with lifestyle or aerobic
activity or targeted weight-loss in both children and parents (Epstein, McCurley, Wing, &
Valoski, 1990; Epstein et al., 1994). However, there does not appear to be enough data to
determine which specific strategy or combination of strategies is more successful than others for
weight loss (Jelalian & Saelens, 1999).
Family-based interventions require parental involvement in the treatment of obese children.
Cooperation is considered critical – parents are able to arrange an environment that may prompt,
model, and reinforce eating and activity patterns which can lead to weight loss or gain. Several
studies have explicitly examined variations of parental involvement and concluded that actively
involving parents in treatment is beneficial (e.g., Brownell, Kelman, & Stunkard, 1983; Coates,
Killen, & Slinkard, 1982; Flodmark, Ohlsson, Ryden, & Sveger, 1993; Israel, Solotar, & Zimand,
1990). In the short-term, studies do not indicate an advantage of parent participation over no
involvement (Kingsley & Shapiro, 1977; Kirschenbaum, Harris, & Tomarken, 1984). However,
studies that document long-term decreases in percent overweight in children include parental
participation as essential treatment components (e.g., Epstein and colleagues). Findings also
suggest that parent involvement in all aspects of treatment for preadolescents is beneficial whereas
a distant support role for adolescents may be more appropriate (Jelalian & Saelens, 1999).
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Physical Activity. Variations of physical activity have been examined in the treatment of
obesity in children. Exercise interventions can be programmed aerobic (i.e., specific type,
intensity, and duration) or lifestyle change (i.e., menu of activities from which to choose; flexible
times and duration). Currently, few data suggest that exercise, independent of dietary change,
results in decreases in percent overweight in children (Jelalian & Saelens, 1999). Generally,
researchers have not found significant differences between interventions of dietary change
combined with exercise and interventions of either diet or exercise alone in the short-term
(Epstein, Wing, Koeske, Ossip, & Beck, 1982; Rocchini et al., 1988). However, the combination
of dietary change and lifestyle or programmed aerobic exercise was superior to a diet and weak
exercise program (i.e., calisthenics) at 10-year follow-up (Epstein et al., 1994). Additional data
indicate that targeting decreases in sedentary behaviors (rather than increases in physical activity)
is associated with decreases in percent overweight (Epstein, Paluch, Gordy, & Dorn, 2000).
These findings suggest that dietary change and some form of regular physical activity are needed
to produce weight loss (or prevent relative weight gain) in children.
Medication. Medication has become popular in the treatment of adult obesity. Medication
is typically reserved for individuals who fail to lose weight or maintain their weight loss after
conventional therapy. The usual practice is to prescribe medication as an adjunct to a program of
dietary restriction and exercise. At present, there are currently no published studies involving
pharmacologic treatment of obesity in children and only three in adolescents. There are two
reports in adolescents of the use of metformin, a medication typically prescribed to improve
glucose tolerance in diabetic patients (Freemark & Bursey, 2001; Kay et al, 2001). Kay and
colleagues (2001) conducted a small randomized, double-blind, placebo controlled trial in 24 nondiabetic obese adolescents who exhibited elevated insulin levels. The research participants were
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placed on a low calorie diet; half were given placebo, half were administered metformin. Although
all adolescents lost weight, those in the metformin treatment group lost significantly more weight
and body fat than those in the placebo group (Kay et al., 2001). Freemark and Bursey (2001) also
conducted a randomized, double-blind, placebo controlled trial of metformin in adolescents.
However, dietary changes were not prescribed as part of the study. At the end of the study, the
placebo and medication group did not differ significantly in weight loss.
The third report tested orlistat, a gastrointestinal lipase inhibitor (McDuffie et al., 2002),
as a treatment for adolescent obesity. The open-label pilot trial investigated the safety and efficacy
in an adolescent population. As such, all subjects were enrolled in a 12-week lifestyle change
program and were prescribed the medication. Although results indicate a significant weight loss
by the end of the 12 weeks, there was no placebo-controlled comparison group – definitive
conclusions cannot be made on the effect of orlistat on body weight in adolescents. In summary,
there are new developments in the medical management of childhood and adolescent obesity;
however, findings are preliminary or in-progress.
Additional Factors Related to the “Success” of Obesity Treatments. Parent weight has
been shown to influence response to obesity treatments. After five years, obese children with
obese parents are less successful at weight control than obese children with normal-weight parents
(Epstein, Wing, Valoski, & Gooding, 1987). Obese children with normal-weight parents adhere
more to changes in diet and physical activity than obese children with obese parents (Epstein,
Wing, Koeske, & Valoski, 1986); normal-weight parents also rate their children as more
successful in implementing and maintaining eating and exercise changes (Epstein et al., 1987).
These findings may be partially explained by the relationship of parent weight and children’s
hedonic ratings of food and physical activity before any weight-loss intervention – palatability and
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enjoyment ratings of food and physical activities have been shown to be consistently lower for
children of obese parents than the offspring of normal-weight parents (Epstein et al., 1989).
Shared family environment increases exposure to specific foods and patterns of exercise, which
can influence preference (Birch & Marlin, 1982). Epstein and his colleagues (1989) conclude that
parent weight may be central in the implementation of and response to obesity intervention –
parent weight may affect preference and acceptability of particular treatment strategies.
Culture is another factor that might moderate acceptability and the success of obesity
interventions. Obesity is less central to self-evaluation and is not equally stigmatized in all cultures
(Abrams, Allen, & Gray, 1993; Burke et al., 1992; Greenberg & LaPorte, 1996; Kumaniyika,
Wilson, & Guilford-Davenport, 1993; Smith, Thompson, Raczynski, & Hilner, 1999).
Researchers suggest that black females experience less social pressure about their weight and have
more positive attitudes about overweight than white females (Kumaniyika et al., 1993). Although
more weight-tolerant attitudes in the AA community may provide a protective factor against the
development of eating disorders (Rodin, Striegel-Moore, & Silberstein, 1990), these attitudes
could actually increase the risk for obesity and obesity-related health problems (Jeffery, 1991;
Kumanyika et al., 1994; Rucker & Cash, 1992). The greater acceptance of higher body weights
(Kemper et al., 1994; Rand & Kuldau, 1990), the higher levels of body satisfaction at heavier
weights (Story, French, Resnick, & Blum, 1995), and the frequent efforts to gain weight
(Schreiber et al., 1996) may all result in the higher rates of obesity observed in black females
(Smith et al., 1999). Research also indicates a shorter duration of dieting and lower levels of
physical activity and fitness among black females than among white females (Kumanyika et al.,
1993; Schreiber et al., 1996). Overall, the attitudinal and behavioral factors might limit the ability
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of some black females to lose weight or maintain weight loss (Kumanyika et al., 1993) and reduce
the acceptability of any anti-obesity treatments.
Some studies have attempted to explain the success (or lack of success) in achieving longterm weight loss by a variety of personality tendencies, such as locus of control (LOC; Nir &
Neumann, 1995). The phrase “locus of control” refers to one’s belief about the extent to which
the individual has control over his/her life. A belief in external control leads to the perception that
reinforcement (e.g., improved health, weight loss) is the result of luck, chance, or fate or that it is
under the control of powerful others. The perception that reward is the result of one’s own selfcontrol indicates an internal locus of control. In particular, LOC has been examined for its
relevance in predicting fluctuations in health status and health behaviors (Wallston, Wallston, &
DeVellis, 1978) as well as in weight loss and dieting behaviors (Saltzer, 1978; Stotland & Zuroff,
1990; Westenhoefer, 2001). The theory posits that those who value health highly and report a
high internal LOC will be more likely to adopt or have a positive attitude toward preventive
behaviors (Norman, Bennett, Smith, & Murphy, 1998), such as the prevention of T2DM or
obesity. Those with a high external LOC will be less likely to endorse (i.e., find acceptable) or
engage in preventive behaviors.
A series of studies applied this theory to obesity and weight loss, with initial studies
providing inconsistent results (Balch & Ross, 1975; Gormally, Rardin, & Black, 1980; Ross,
Kalucy, & Morton, 1983; Tobias & MacDonald, 1977). However, LOC seems to be a better
predictor of weight loss when the value of health and appearance is considered. Individuals with a
higher internal LOC and value for health or appearance have been found to be more likely to
consume healthy foods than individuals with an external LOC (Bennett, Moore, Smith, Murphy,
& Smith, 1994; Saltzer, 1978). In addition, individuals with an internal LOC are more likely than
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those with an external LOC to maintain their weight loss up to two years, despite no weight-loss
differences between groups at the end of treatment (Nir & Neumann, 1995). However, this effect
diminishes after a two-year period. Thus, the belief in one’s ability to control weight (an internal
LOC) and a corresponding value of health/appearance may affect acceptability and maintenance of
weight-loss interventions and obesity prevention efforts.
Brief Review of T2DM Prevention Studies
The recent surge in T2DM prevalence has stimulated research pertaining to the prevention
of the disease during the past 10 years. However, there is a paucity of studies concerning the
prevention of childhood T2DM. The close link to obesity has prompted researchers to suggest
that T2DM is a complication of obesity and that the prevention of obesity will, in effect, delay or
prevent the onset of T2DM (Anderson, 2000; Pinhas-Heimel & Zeitler, 2000; Young et al.,
2000). Preliminary findings point to this possibility.
Dietary Change/Weight Loss. Acute energy restriction and weight loss have been shown
to improve insulin sensitivity and improve glycemic control in obese patients with T2DM (Henry,
Scheaffer, & Olefsky, 1985; Kelly et al., 1993). In addition, long-term weight loss has been shown
to delay the onset of T2DM in obese adults without T2DM (DPP Research Group, 2002; Klein,
2001; Pan et al., 1997; Swinburn, Metcalf, & Ley, 2001). Data from a 16-year observation period
of the Framingham Study indicate that the risk of T2DM was reduced by one-third in those who
lost 3.0-7.5 kg. and by one-half in those who lost greater than 7.5 kg. (Moore et al., 2000).
Weight loss achieved by gastric surgery is associated with a five-fold decrease in the risk of
T2DM during an 8-year observation period after surgery (Sjöström, Peltonen, Wedel, &
Sjöström, 2000). Although little is known at this time about T2DM prevention with weight
loss/dietary changes in children, these findings suggest the possibility that preventing weight gain
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in children/adolescents may delay or prevent the onset of T2DM. Ongoing research is examining
this possibility (Sudi et al., 2001).
Physical Activity. Clinical, epidemiological, and basic research in adults suggests physical
activity as a tool for prevention of chronic disease and enhancement of overall health (Haskell et
al., 1992; Pate et al., 1995). In children, the replacement of sedentary behaviors (e.g., television
viewing, computer games) by activities of moderate intensity may enhance overall health and
assist in preventing chronic disease in at-risk youth (Epstein, Coleman, & Myers, 1996; Sheldahl,
1986). The effect of regular exercise training on individuals with T2DM is widely accepted
(Bonen, 1995). A single bout of exercise increases blood flow and glucose delivery, adding to the
effect of maximal insulin concentrations (Flemming, Mikines, Sonne, & Galbo, 1994). Preliminary
data indicate that the effect increases with regular exercise training (Flemming et al., 1994). These
findings led Sothern and colleagues (1999) to suggest that the health benefits of
exercise/resistance training in children may be similar to that of adults – regular physical activity
might improve insulin sensitivity and possibly delay or prevent the onset on T2DM in children.
However, the potential health benefits of increased physical activity for high-risk youth are still
under investigation.
Medication. Children and adolescents are exhibiting impaired glucose tolerance (IGT;
“pre-T2DM”) at younger and younger ages (Young-Hyman et al., 2001). Medications that
increase glucose tolerance in diabetic patients (e.g., metformin) might prove useful in preventing
the progression of IGT to glucose intolerance in these high-risk youth. In obese non-diabetic
adults, metformin has been shown to delay the onset of T2DM by approximately 31% for at least
three years (DPP Research Group, 2002). Although there are far fewer pediatric studies
examining the effects of medication on the development of T2DM, preliminary findings provide
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limited support for the use of medication as a prevention strategy (Freemark & Bursey, 2001; Kay
et al., 2001). Freemark and Bursey (2001) conducted a small double-blind, placebo-controlled
study of the effects of metformin on BMI, and insulin and glucose blood levels in obese
adolescents with fasting hyperinsulinemia. They found that metformin treatment was associated
with slight reductions in BMI and fasting blood glucose and insulin concentrations. However, the
changes were small in magnitude, prompting the researchers to conclude that metformin might
complement the effects of lifestyle interventions in high-risk youth, a conclusion supported by
studies combining diet with metformin (Kay et al., 2001).
Lifestyle Change. Early lifestyle intervention studies on individuals with IGT and with
newly diagnosed T2DM have provided encouraging results (Eriksson & Lindgärde, 1991;
Laitinen et al., 1993; Pan et al., 1997; Tuomilehto et al., 2001; Uusitupa, 1996; Wing, Polley,
Venditti, Lang, & Jakicic, 1998) – moderate changes in weight, diet, and physical activity can
result in significant improvements in glucose tolerance, potentially reversing the development of
T2DM. As a result, two large multi-site, randomized control trials have been conducted to
determine whether it is possible to prevent T2DM by lifestyle change or medication in individuals
with a high risk of diabetes.
The Finnish Diabetes Prevention Study (DPS) examined the effects of a lifestyle change
intervention (i.e., intensive diet and exercise program) in 523 overweight adult subjects with IGT.
Preliminary data at one-year follow-up indicated a significant reduction in body weight and
improvement in glucose tolerance in the intervention group (Eriksson et al., 1999); at two years,
subjects had maintained their weight loss and demonstrated an improvement in physical fitness
(Uusitupa et al., 2000). The DPS researchers recently announced the four-year results – a lifestyle
change program effectively delayed the onset of T2DM (cited in DPP Research Group, 2000).
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In the U.S., the Diabetes Prevention Program (DPP) compared the effects of a lifestyle
intervention with metformin or placebo on the development of diabetes in 3234 overweight adults
with IGT (DPP Research Group, 2002). The lifestyle intervention involved training in diet,
exercise, and behavior modification in 16 sessions during the first 24 weeks, then monthly. At
three years, almost 40% of participants in the lifestyle condition had a weight loss of at least 7%
and 58% had met the goal of 150 minutes of weekly physical activity. Participants in the
medication intervention took metformin twice daily, with 72% of participants in this condition
taking at least 80% of their prescribed doses. At three years, there was minimal weight loss (2.1
kg.) and no significant change in level of physical activity in the medication condition. The
lifestyle intervention reduced the risk of developing T2DM by 58% and metformin by 31% when
compared to placebo. The interventions were effective in men and women and in all ethnic groups
(DPP Research Group, 2002). The findings that lifestyle change can delay the onset on T2DM for
at least three years prompted the DPP research group and funding institution to end the study
early.
Among children and adolescents, T2DM is probably as closely linked to the modifiable
risk factors (i.e., obesity, poor nutrition, and physical inactivity) as it is among adults (Expert
Committee, 1999). Because childhood and adolescence are periods when behaviors are
established, increasing physical activity and decreasing obesity might reduce the incidence of
T2DM and prevent other chronic diseases (Fagot-Campagna et al., 2000). Preliminary results
indicate that a short-term diet and exercise/sports intervention program can reduce adiposity and
improve insulin sensitivity (Sudi et al., 2001). In recent years, community and school interventions
targeting high-risk youth have begun to promote physical activity and improved diet (Cook &
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Hurley, 1998; Dean, 1998; Teufel & Ritenbaugh, 1998). However, the long-term effectiveness of
these programs is not yet established.
Potential Factors Related to the “Success” of T2DM Prevention and Treatment. As
discussed, strategies to prevent obesity are being increasingly studied for their effects on the
development of T2DM in children. Therefore, the factors that affect the success of obesity
treatments will most likely have the same effects in T2DM prevention strategies. It is not known
at this time if the perceived severity of the disease potential will affect treatment adherence.
Evidence suggests that a significant proportion of parents with T2DM do not believe that
prevention of T2DM is possible (external locus of control) or that their children are likely to
develop the disease (Pierce, Hayworth, Warburton, Keen, & Bradley, 1999). The belief that any
preventive strategy is futile or unnecessary will likely impede treatment acceptability and
adherence.
In addition, children and adolescents with T2DM are usually asymptomatic and do not feel
ill. Treatment of T2DM can require extensive lifestyle changes, including dietary changes,
frequent blood glucose monitoring, daily oral medication and/or insulin injections, and
recommended increases in physical activity and/or weight loss. Adherence to this strict medical
regimen is typically low. Treatment itself can require painful injections or produce side effects
more distressing than the symptoms of the disease (Callahan & Mansfield, 2000). In addition,
nonadherence to treatment has few acute physical consequences. As a preventive strategy, it is
likely that medication therapy will show a similar level of nonadherence (Callahan & Mansfield,
2000) with lower ratings of acceptability.
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Summary of Obesity and T2DM Interventions
In general, several factors appear to influence the “success” of obesity (and T2DM)
interventions in children. Behavioral methods have met with more success than purely nutrition
education formats. Parental participation in some form seems to be associated with long-term
maintenance of relative weight loss for children, through reinforcement and/or modeling of dietary
changes and physical activity, although parental obesity may negate these effects. Increasing
physical activity and/or decreasing sedentary behaviors appear to be related to long-term efficacy
of obesity treatments, although the effects on T2DM development in children are unknown at this
time. Social acceptance of higher weights in some cultures and an external locus of control may
curtail the success of obesity and T2DM interventions. Overall, Jelalian and Saelens (1999)
conclude that the most successful interventions minimize the “cost” associated with adherence;
that is, interventions that minimize the effort and inconvenience of strategies tend to produce
more favorable outcomes. This conclusion coincides with general findings in treatment
acceptability research – an intervention requiring less time and effort is more likely to be rated
acceptable.
Treatment Acceptability Research
Treatment acceptability research flourished about 20 years ago, when behavior therapy
was first becoming ‘mainstream.’ Investigators found that equally efficacious treatments were not
necessarily equally acceptable to consumers (Kazdin, 1981). A basic hypothesis of this line of
research is that acceptable treatments are more likely to be sought out, implemented, adhered to,
and maintained (Frentz & Kelley, 1986; Kazdin, 1980a, 1981; Wolf, 1978). In general, treatment
acceptability refers to the “judgments about the treatment procedures by nonprofessionals,
laypersons, clients, and other potential consumers of treatment” (Kazdin, 1980a, p. 259). For a
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treatment to be considered acceptable, it must be appropriate to the problem, reasonable,
nonintrusive, and “meet with conventional notions about what treatment should be” (Kazdin,
1980a, p. 259).
This method could be applied to a new problem –prevention and treatment of obesity and
T2DM. As described, most childhood anti-obesity/T2DM interventions employ behavioral
strategies. Although several aspects of the prevention/treatment strategies have been shown to be
efficacious, the procedures must also be accepted by the individuals who use them. If participants
do not like specific interventions offered, they are less likely to implement the treatment with
integrity, and maintenance of behavior change is unlikely (Kazdin, 1977; Miller & Kelley, 1992;
Wolf, 1978).
The majority of published research on treatment acceptability has focused on interventions
aimed at changing child conduct problems, e.g., self-injury, aggression. Typical interventions
examined include a variety of behavioral procedures, medication, spanking, and contingent
electric shock. The methodology is primarily analogue – raters are presented with a written case
description of the child exhibiting a problem behavior along with a written description of
treatment procedures that can be applied to the problem; the rater then completes an acceptability
rating scale for each treatment as applied to that problem. Researchers generally use potential or
actual consumers to rate the interventions (e.g., parents, institutional staff), increasing the
ecological/social validity of the analogue studies. Few studies have measured acceptability after
treatment implementation (consumer satisfaction studies; e.g., Reimers & Wacker, 1988).
Because of similar treatment characteristics, general treatment acceptability findings could
be extended to obesity interventions. Overall, acceptable interventions tend to be the least
restrictive, require little time to implement, have the fewest side effects, and are the least
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disruptive to others (Elliott, 1988; Kazdin, 1980a). Nutrition education could be considered as the
least restrictive and least time-consuming, with no obvious side effects, and as non-disruptive to
others. However, nutrition education alone has not been shown to have any effect on weight
reduction. The more “successful” behavioral interventions for obesity tend to be reinforcementbased and vary in the amount of time and effort required of parents and children/adolescents,
possibly influencing treatment preference and acceptability. Findings from earlier treatment
acceptability studies on problems other than obesity suggest that the typical reinforcement-based
obesity intervention would be rated as more acceptable than medication (a potential future
intervention). However, as more parental involvement is required, treatment acceptability ratings
may decrease (e.g., reinforcement of physical activity alone vs. family-based intervention). In
addition, positive reinforcement-based procedures are consistently rated more acceptable than (1)
restrictive or punishment-based treatments or (2) medication (Jones, Eyberg, Adams, & Boggs,
1998; Reimers, Wacker, & Koeppl, 1987; Tarnowski, Simonian, Park, & Bekeny, 1992; Witt &
Elliott, 1985). Treatments viewed as strong, controlling, and intrusive to the client and problem
tend to be rated as the least acceptable (Kazdin, 1980b). Treatments with adverse side effects are
also associated with lower acceptability ratings (Kazdin, 1981). Gene therapy and medication are
anti-obesity strategies that could be considered as strong and intrusive with (possible) adverse
side effects. These interventions would probably be rated as the least acceptable for the
prevention of obesity.
Rater characteristics that have been studied include ethnicity and income. Ethnic
background of the rater and socioeconomic status (SES) have not consistently influenced ratings
of treatment acceptability (Heffer & Kelley, 1987; Tarnowski et al., 1992). However, slight
differences in treatment acceptability ratings according to ethnicity and income suggest that
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further research is warranted. For example, Heffer and Kelley (1987) found that low-income black
mothers generally favored less labor-intensive treatments, though this finding was not statistically
significant. It is conceivable that this relationship may have relevance for some obesity/T2DM
interventions that are labor-intensive.
Severity of targeted behaviors is another factor thought to influence treatment
acceptability ratings. These findings are particularly salient for obesity/T2DM interventions and
culture. Caregivers must consider obesity and T2DM to be potential health risks before deciding
treatment is appropriate. Generally, most studies indicate that treatments are more acceptable for
more severe problems (Reimers et al., 1987). Specifically, restrictive procedures are considered
more acceptable for the more severe problems whereas reinforcement-based procedures are rated
more acceptable for mild behavior problems (e.g., Tarnowski, Rasnake, Mulick, & Kelly, 1989;
Miltenberger, Parrish, Rickert, & Kohr, 1989). However, evidence suggests that a significant
proportion of black parents whose children are obese or “super-obese” do not consider their
children’s weight as a health risk (Young-Hyman, Herman, Scott, & Schlundt, 2000). Additional
findings indicate that parents with T2DM do not consider their children as at-risk for developing
diabetes (Pierce et al., 1999). These findings may translate into lower acceptability ratings for
anti-obesity/T2DM interventions for black parents when compared to white parents.
Treatment Acceptability and Adherence. Simply knowing that one treatment is more or
less acceptable than another does not clarify whether the most acceptable treatment is also the
most likely to be implemented with integrity. Early investigators suggested a positive (and causal)
relationship between acceptability and treatment adherence (Kazdin, 1980a; Wolf, 1978) and
existing models continue to associate acceptability with treatment use and integrity (Eckert &
Hintze, 2000). Although there has been limited research testing these models, clinical findings
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suggest a moderate relationship between treatment use/adherence and its level of acceptability to
parents (Reimers, Wacker, Cooper, & De Raad, 1992a, 1992b; Walle, Hobbs, & Caldwell, 1984).
Reimers and colleagues (1992b) compared parental acceptability ratings of various analogue
treatments to ratings of treatments actually recommended to the parents for the behavioral
problems of their children. The researchers found that treatments were distinguished by their
acceptability ratings by actual consumers, i.e., parents seeking treatment for their children. This
finding suggests some correspondence between analogue and naturalistic assessments.
Reimers and colleagues then examined parental levels of acceptability and treatment
adherence at various times before and after treatment initiation (Reimers & Wacker, 1988;
Reimers et al, 1992a, 1992b). Parents who rated the recommended treatments as the most
acceptable reported higher levels of adherence and treatment effectiveness at 1-, 3-, and 6-month
follow-up than parents who rated their recommended treatments as less acceptable. In addition,
parents’ level of adherence to treatment at one month was significantly related to their ratings of
acceptability at three months. The investigators suggested that initial acceptance refers to a
willingness to implement a specific treatment and that this willingness is a prerequisite for initial
treatment adherence. However, other variables associated with treatment acceptability (i.e.,
effectiveness and reasonableness) are important for the long-term maintenance of adherence (at 3and 6-months). These clinical findings provide preliminary support for the relationship between
treatment acceptability and use/adherence, however, additional research is necessary to further
clarify the relationship (Finn & Sladeczek, 2001).
Summary, Rationale, and Design
Pediatric obesity and associated health-risks, such as T2DM and CVD, have increased
dramatically over the past 30 years, with the greatest rise in black female children and adolescents.
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Obesity and T2DM prevention efforts are increasing and show promising long-term results.
However, several variables affect the success of prevention efforts, variables that require parental
acceptance and participation. If parents do not like or accept the procedures, long-term behavior
change in children to treat and/or prevent weight gain and T2DM will probably not occur. In
addition, the imminent identification of “obesity genes” may dramatically affect what parents are
willing to consider as viable treatment alternatives.
The present study is the first to examine the differential effects of ethnicity, parent weight,
and genetic predisposition to obesity or T2DM on parents’ perceptions of six prevention
treatments. Independent variables included parent/child ethnicity (AA, Caucasian), genetic
probability of becoming obese or developing T2DM (Obesity, T2DM), and maternal weight status
(Normal, Overweight/Obese). Thus, the design of the present study is a 2 (ethnicity) x 2 (type of
problem) x 2 (weight status) x 6 (treatment) multi-factorial design. The treatment procedures
rated included the following: (a) no treatment, (b) physical activity alone, (c) medication, (d)
dietary change alone, (e) gene therapy, and (f) family lifestyle change (i.e., behavioral modification
of dietary change and physical activity). These interventions, with the exception of gene therapy,
represent the range of treatments commonly studied in obesity prevention and treatment research.
Gene therapy was included because the possibility of genetic modification increases with
the identification of obesity genes and subsequent susceptibility testing. Studies using animal
models have reported short-term success in the treatment of obesity and diabetes with gene
therapy (Muzzin, Eisensmith, Copeland, & Woo, 1996) and ongoing animal studies are exploring
the long-term effects of gene therapy in obesity treatment and T2DM prevention (Dhillon et al.,
2001; Murphy et al., 1997). Two additional treatments have been typically studied – nutrition
education and child lifestyle change. However, pilot study results and expert opinion indicated
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that the treatments were perceived as the same as two other treatments (nutrition education v.
dietary change; child lifestyle change v. family lifestyle change). Thus, nutrition education and
child lifestyle change were eliminated as treatment options due to slight perceived differences in
method and ratings. The “no treatment” option was included due to an unexpected level of
acceptance and the variability in ratings, derived from the pilot study.
Hypotheses
Based on the previous discussion, the specific hypotheses of the present study are as follows:
Hypothesis 1. Ethnic background of parents was expected to influence acceptability for
obesity prevention strategies. The greater acceptance of and body satisfaction at higher weights in
the AA community was hypothesized to translate into lower acceptability ratings of anti-obesity
treatments for AA parents than for Caucasian parents.
Hypothesis 2. Parent weight has been shown to influence adherence to and response to
anti-obesity/T2DM interventions, possibly due to lifestyle behaviors already present in the family
environment. It was hypothesized that Normal weight parents would rate the behaviorallyoriented treatments as more acceptable than Overweight/Obese parents.
Hypothesis 3. It was hypothesized that perceived severity of the condition would affect
treatment acceptability. Parents, regardless of ethnic background or weight status, would rate all
treatments for T2DM as more acceptable than the same preventive treatments for obesity. It was
also expected that that the more intrusive treatments would be rated as more acceptable for
T2DM than for obesity prevention.
Hypothesis 4. It was hypothesized that weight status would interact with ethnic
background to affect acceptability of anti-obesity treatments. Overweight/Obese AA parents
would rate treatments for obesity as less acceptable than Caucasian parents of all weights. Normal
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weight AA parents would rate the preventive treatments for obesity as less acceptable than
Caucasian parents, although not to the degree of their Overweight/Obese counterparts. Parent
weight and ethnic background were not expected to influence acceptability ratings for the T2DM
interventions (see Hypothesis 3).
Hypothesis 5. It was hypothesized that locus of control would be correlated with ratings
of treatment acceptability. Overall, parents with an external LOC would rate more intrusive
treatments as more acceptable than parents who endorse an internal LOC and this effect would be
mediated by personal weight/appearance concerns and previous dieting attempts. Specifically,
parents with an external weight-related LOC would rate the more intrusive treatments for obesity
more acceptable than parents with an internal weight-related LOC. Parents who endorsed an
external health-related LOC would rate the more intrusive treatments for T2DM as more
acceptable than parents with an internal health-related LOC.
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Method
Pilot Study
A sample size of 112 parents was chosen based upon a power analysis using data collected
in a pilot study that used an identical procedure and a similar sample of parents. Measures of
central tendency and variance from this study were used to assess statistical power to detect
differences in treatment acceptability ratings. With a sample size of 112 parents (14 subjects in
each of the eight groups), a large effect size of 1.00 SD should be detected with 80% power.
Inclusion/Exclusion Criteria
Subjects were included according to female gender, ethnic background (AA, Caucasian),
age (25-50 years), and weight status (Normal, Overweight/Obese). Normal weight was defined by
a BMI of 19-24.9 kg/m2 and Overweight/Obese by a BMI of 25-45 kg/m2. Exclusion criteria
included male gender, a history of diabetes, or previous participation in research sponsored by the
Pennington Biomedical Research Center (a non-profit institution that specializes in nutrition and
preventive medicine research). Parents with a history of diabetes were excluded due to the
probable effects on treatment ratings (e.g., personal experience with treatment difficulties may
bias ratings). Parents whose children had been diagnosed with diabetes were also excluded for the
same reason.
The Obesity Expert Committee recommends that research and treatment of childhood
obesity begin as early as two years old (Barlow & Dietz, 1998), although most obesity prevention
research focuses on the 5-17 age range. The 2000 U.S. Census reported that parents of children in
the selected age range (2-17 years) are primarily 25 to 50 years old (U.S. Census Bureau, 2001),
thus, the selection of the maternal age range.
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Recruitment
Participants were recruited from the database at Pennington Biomedical Research Center
(PBRC). Relevant variables in the database included gender, age, ethnicity, presence of T2DM,
previous participation in PBRC-sponsored research, and weight at time of initial contact. Over
7,000 potential subjects met the gender, age, ethnic background, weight, and absence of diabetes
or previous research experience criteria and comprised this sample of convenience.
Initially, fifty participants were mailed the study materials and a small gift (i.e., 45-minute
phone card). However, after two weeks, the response rate to this strategy was less than 5% (n =
2). In reaction to this low response rate, the study materials were mailed to another 50 individuals
with a promise of a gift that they may choose (i.e., $10 gift card at a local store). Once the study
materials were returned, the $10 gift card was mailed to their address. Because the response rate
to this second strategy was 28% (n = 14), this strategy was used for the remainder of the study.
Participants
The sample of 7000 potential participants who met inclusion criteria at the time of initial
contact was stratified by ethnicity and weight status. A total of 650 packets were mailed to
potential participants randomly selected from the stratified sample. Of these, 72 packets were
returned by the postal service due to incorrect or vacant addresses. Of the remaining 578 packets
mailed, 11 packets were returned by recipients who did not complete the packets due to exclusion
criteria (i.e., child out of age range, mother out of age range, or unknown reasons). Also, there
were a total of 183 completed packets returned. Therefore, the total return rate for this study was
33.6% (n = 194). However, an additional 37 participants were excluded due to maternal age (n =
15), child age (n = 4), and incorrect responses to the procedural question (n = 18). The
procedural question was included at the end of the packet and asked participants to indicate how
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they completed the treatment acceptability questionnaires (Appendix A). A total of 146 females
met the inclusion criteria and were included in the final data analyses.
Participants were 146 females whose children were between the ages of 2 and 17 years.
Participants in this study ranged from 25 to 50 years old, with a mean age of 39.5 years. The
ethnic composition of the sample was split: 47.9% were African-American (n = 70), and 52.1%
were Caucasian (n = 76). In addition, 39.7% of the sample were normal weight (n = 58), with an
average BMI of 22.70 (SD=1.81). The remaining 60.3% were overweight (n = 88), with an
average BMI of 32.22 (SD=5.55). The participants were assigned to groups according to
ethnicity, weight status, and type of problem case description (Obesity, T2DM) presented in the
packet. The number of participants in each group is summarized in Table 1.
Table 1: Number of participants according to group.
African-American
Type of
Problem
Description

Caucasian

Normal
weight

Overweight

Normal
weight

Overweight

Total

Obesity

9

31

17

23

80

T2DM

14

16

18

18

66

Materials
Demographic questionnaire (Appendix B). Participants completed a demographic
questionnaire that included participant’s age, ethnicity, and marital status; years of formal
education; and household annual income. The questionnaire also included the participant’s height,
weight, personal and family medical history, and questions about previous weight loss attempts.
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Questions about their child’s age, gender, height, weight, presence of diabetes, and experience
with health care services were included.
Body Shape Questionnaire – short form (BSQ-sf; Evans & Dolan, 1993; Appendix C).
Parent preoccupation about body weight might affect treatment acceptability ratings. The BSQ-sf,
an eight-item measure of concern about body weight and shape, was used to assess parental body
dissatisfaction and its relation to treatment acceptability ratings.
Weight Locus of Control Scale (WLOC; Saltzer, 1982; Appendix D). The WLOC scale is
a four-item measure that assesses the beliefs that individuals have in the amount of perceived
control they have over their weight. The WLOC was designed to measure expectancies for locus
of control with respect to personal weight and has been found to primarily measure the rejection
of uncontrollable factors within the individual as causes of being overweight (e.g., luck, genes,
fate; Stotland & Zuroff, 1990). The WLOC demonstrates moderate test-retest reliability and
convergent validity (Saltzer, 1982) and is the most commonly used measure of weight LOC.
Multidimensional Health Locus of Control Scale (MHLC; Wallston et al., 1978; Appendix
E). The MHLC is an 18-item measure that consists of three subscales designed to assess beliefs an
individual has about the level of control over his/her health. The Internal scale assesses the degree
to which an individual believes that his/her own behavior is responsible for health or illness. The
Chance scale (external) measures beliefs that an individual’s level of health or illness is a function
of luck, chance, fate, or uncontrollable factors. The Powerful Others (external) scale assesses an
individual’s beliefs that the degree of health or illness is determines by important figures such as
physicians or friends. All items are rated on a 6-point Likert-type format with a reading level of
5th-6th grade. Internal consistency is high for the three subscales (coefficient alpha ranges from
0.67 to 0.77). The MHLC has been shown to predict behavioral involvement in personal health
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care (Rock, Meyerowitz, Maisto, & Wallston, 1987). The Chance and Powerful Others scales
were used to define external health-related LOC; the Internal scale defined the level of internal
health-related LOC.
Case Descriptions (Appendix F). Mothers were presented with a description of the HGP
and the anticipated identification of obesity and diabetes genes. They were asked to imagine their
child in one of two case descriptions. One case description provided information on the health and
psychosocial risks of childhood obesity along with the probability that her child would become
obese. A second case description described the health and psychosocial risks of T2DM in
childhood as well as the probability of her child developing the disease. Both case descriptions
were subjected to expert review during the planning phase of the study and were deemed
appropriate.
Treatment Options (Appendix G). Parents were presented with six methods which might
be used to prevent the development of obesity and T2DM: no treatment; dietary change; physical
activity; medication; family lifestyle change; and gene therapy. Only the medication treatments
were described differently for the obesity and T2DM case descriptions; benefits and side effects
were modeled on the current drugs of choice for the two conditions (i.e., sibutramine for obesity,
metformin for T2DM). Treatment descriptions were written at the 5th to 6th grade level; all
contained between 126 to 197 words. All six treatments were presented randomly after each case
description to control for sequencing effects. Treatment descriptions were also reviewed and
edited by experts in obesity/T2DM research during the planning stage of the study.
Treatment Evaluation Inventory – short form (TEI-sf; Kelley, Heffer, Gresham, & Elliott,
1989; Appendix H). The TEI-sf, a 9-item questionnaire designed to measure an adult’s
acceptance of treatments used with children, will be used to evaluate the acceptability of each
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treatment. Each TEI-sf item is rated on a five-point Likert-type scale. The TEI-sf has an overall
reading level of 4.2 and demonstrates high internal consistency (coefficient alpha = .85; Kelley et
al., 1989). The TEI-sf has also been shown to discriminate among alternative treatment methods
(Adams & Kelley, 1992; Kelley et al., 1989). The measure was slightly altered to focus on
obesity/T2DM treatments rather than child conduct problems.
Procedure
Participants were mailed a packet containing the demographic questionnaire, case
description, treatment descriptions (each followed by a TEI-sf), BSQ-sf, WLOC, and the MHLC.
They were informed that the researchers are interested in obtaining parents’ opinions about
several methods used to prevent weight gain and disease development in children. Participants
were instructed to complete the packet in the order it was given to them without looking forward
or backward in the packet. Fifty percent of the mailed packets asked mothers to answer the
questions in reference to their youngest child between the ages of 2 and 17 years; 50% included
instructions to answer question regarding their oldest child within the age range. They were then
asked to return the study materials in the enclosed addressed stamped envelope.
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Results
Missing Data
The imputation method used to estimate missing item values was mean substitution
according to group membership. There were 7 cases with one item response missing, 21 cases
with two item responses missing, 4 cases with three item responses missing, and 2 cases with five
item responses missing. There was no discernible pattern in the missing values.
Demographic Characteristics
Analyses of demographic variables were conducted in order to determine whether
different groups were comparable with respect to a variety of descriptive characteristics. Chisquare analyses of dichotomous variables (i.e., employment status, marital status, sex of target
child) were performed. Results indicated that the groups differed in employment status, according
to weight status, Χ2 = 6.20, p < .05. Overweight participants (n = 75; 85.2%) were more likely
than Normal weight participants (n = 40; 69.0%) to be employed. In addition, a significant
difference in marital status was found between AA and Caucasian mothers, Χ2 = 37.22, p < .0001.
Specifically, more Caucasian mothers (n = 69, 47.3%) were married than were AA mothers (n =
32, 21.9%). However, there were no differences in marital status according to weight status or
type of problem. In addition, employment status and the sex of the target child did not differ
across subgroups of parents.
Analyses of variance were used for the comparison of groups on continuous dependent
variables (see Table 2). The ANOVAs were conducted with three between-group variables –
ethnicity, maternal weight status, and type of problem. Results indicated that the
Overweight/Obese group weighed significantly more than the Normal weight group, F(1, 146) =
143.72, p < .0001. The Overweight group reported significantly more prescribed medications than
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the Normal weight group, F(1, 146) = 10.25, p < .01. In addition, the Overweight group reported
a significantly lower total annual income than the Normal weight group, F(1, 146) = 10.01, p
<.01. Total annual income also differed according to Ethnicity; AA mothers (M = $41,562.15, SD
= 32307.72) reported a significantly lower total annual income than the Caucasian mothers (M =
$71,854.33, SD = 28704.57), F(1, 146) = 29.06, p < .0001. Maternal age and years of education
did not differ according to ethnicity, weight status, or type of problem. Table 2 summarizes the
findings for demographic variables according to weight status.2
Comparisons of child variables indicated that the target children of the Overweight group
weighed significantly more than the children of the Normal weight group, F(1, 124) = 4.50, p <
.05. Target child BMI also differed according to Ethnicity; AA children (M = 22.06, SD = 6.78)
weighed significantly more than Caucasian children (M = 19.86, SD = 5.65), F(1, 124) = 4.83, p
< .05. Target child age, number of prescribed medications, and level of health care did not differ
according to ethnicity, weight status, or type of problem (see Table 2).
Questionnaire Data
An analysis of covariance (ANCOVA) was conducted to identify group differences in
subjects’ scores on the BSQ. Between-group variables were ethnicity, maternal weight status, and
type of problem. Total annual income, a measure of SES, was included as a covariate due to its
relationship with both the ethnicity and weight status variables. A main effect of ethnicity, F(1,
146) = 4.07, p < .05, was revealed, suggesting that Caucasian mothers were less satisfied with
their bodies (M = 28.43) than were AA mothers (M = 25.67). A main effect of weight status, F(1,
146) = 33.06, p < .001, was also revealed. Overweight mothers were significantly less satisfied
with their bodies (M = 30.23) than were Normal-weight mothers (M = 22.37). This analysis did
not reveal a significant ethnicity by weight interaction, F (1, 146) = 2.69, p = .10, failing to
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support previous research findings of higher levels of body satisfaction at heavier weights in the
AA culture (Kumaniyika et al., 1993).
Table 2: Summary of means and standard deviations of demographic characteristics by
weight status.
Demographic
Characteristic

Normal weight
(n=58)

Overweight
(n=88)

Age

38.45
(6.04)

40.28
(6.55)

BMI

22.70*
(1.81)

32.22*
(5.55)

Years of education

15.18
(2.73)

14.57
(2.60)

Total annual income

$68,562.43*
(38,296.79)

$49,927.94*
(28,671.00)

Number of prescribed
medications

0.72*
(0.93)

1.47*
(1.58)

Target child age

9.22
(4.88)

11.10
(4.68)

Target child BMI

19.10*
(4.57)

22.06*
(6.85)

Level of health care

3.27
(0.95)

3.30
(1.06)

Number of prescribed
medications for target child

0.47
(1.03)

0.44
(0.84)

Note: BMI = Body mass index. Level of health care items were rated on a 5-point Likert
scale (1=significantly below average; 5=significantly above average). Standard deviations are in
parentheses. * indicates that group means differ at p < .01.
A multivariate analysis of covariance (MANCOVA) was conducted to identify group
differences in subjects’ scores on the MHLC subscales and the WLOC. The groups did not differ
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significantly on the LOC measures. Means and standard deviations of subjects’ scores on the
assessment measures according to weight status are presented in Table 3.
status.

Table 3: Summary of means and standard deviations of assessment measures by weight
Assessment
Measure

Normal weight
(n=58)

Overweight
(n=88)

BSQ-sf

22.67*
(8.30)

30.23*
(9.38)

WLOC

9.41
(2.93)

9.97
(3.18)

MHLC-I

26.70
(4.10)

27.26
(3.78)

MHLC-C

16.63
(4.07)

16.70
(4.15)

MHLC-PO

18.37
(4.43)

19.00
(4.67)

Note: BSQ-sf = Body Shape Questionnaire – short form; WLOC = Weight Locus of
Control Scale; MHLC-I = Multidimensional Health Locus of Control Scale – Internal subscale;
MHLC-C = Multidimensional Health Locus of Control Scale – Chance subscale; MHLC-PO =
Multidimensional Health Locus of Control Scale – Powerful Others subscale. Standard deviations
are in parentheses. * denotes significance at p < .01.
Scale Reliability
The TEI-sf was originally developed to determine the acceptability of interventions
targeting child behavior problems – none of the previous research using the TEI-sf specifically
focused on the acceptability of obesity or T2DM prevention strategies. Therefore, reliability
(internal consistency) analyses were conducted on the TEI-sf measures for each treatment type.
Separate analyses were conducted for each type of problem, obesity and T2DM. Inter-item
correlations were calculated for each treatment measure using Cronbach’s alpha.
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Acceptable levels of reliability were found for each treatment type. Table 4 presents
reliability estimates for the TEI-sf at each treatment level for obesity. Cronbach’s alpha for the
TEI-sf at each treatment level ranged from .87 (physical activity) to .91 (no treatment). Table 5
presents reliability estimates for the TEI-sf at each treatment level for T2DM. Cronbach’s alpha
for the TEI-sf at each treatment level ranged from .77 (physical activity) to .92 (gene therapy).
Table 4: Reliability of TEI-sf (at each treatment type) for Obesity problem.
Treatment

Coefficient α

No treatment

0.91

Medication

0.88

Gene therapy

0.89

Diet only

0.89

Physical activity

0.87

Family lifestyle change

0.87

Table 5: Reliability of TEI-sf (at each treatment type) for Type 2 Diabetes problem.
Treatment

Coefficient α

No treatment

0.89

Medication

0.91

Gene therapy

0.92

Diet only

0.86

Physical activity

0.77

Family lifestyle change

0.88
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Group Analyses
To evaluate the effects of ethnicity, maternal weight, and type of problem on TEI scores, a
2 x 2 x 2 x 6 mixed ANCOVA was performed with three between subject variables (ethnicity,
maternal weight status, type of problem) and one within subject variable (treatment). Because low
SES has been found to be associated with higher body weights and health risk behaviors
(Winkleby et al., 1998; Lowry, Kann, Collins, & Kolbe, 1996), the possible influence of SES on
treatment acceptability ratings was controlled for by including SES as a covariate. Therefore, total
annual income, a measure of SES, was entered as a covariate due to its relationship to both the
ethnicity and weight status variables.
A significant main effect for treatment, F(5, 137) = 176.51, p < .0001, was obtained. Post
hoc comparisons using the Tukey method indicated significant differences among most of the
treatments. Mothers rated family lifestyle change (M = 38.02, SD = 5.32) as significantly higher
than all other treatments, suggesting that this intervention was more acceptable than the remaining
treatments. Diet (M = 34.69, SD = 5.67) and physical activity (M = 35.75, SD = 4.93) were rated
as similarly acceptable; both were rated significantly higher than the remaining treatments. Gene
therapy (M = 23.40, SD = 7.37) was rated significantly higher than both no treatment and
medication. The post-hoc comparisons yielded no difference between no treatment (M = 20.67,
SD = 6.96) and medication (M = 18.99, SD = 7.15).
It was hypothesized that ethnic background of the raters would influence treatment
acceptability ratings (see Hypothesis 1). Although a main effect for ethnicity was not found, the
analysis yielded a significant interaction of ethnicity by treatment type, F(1, 137) = 2.43, p < .05.
Table 6 presents the mean TEI-sf scores and standard deviations of the treatments according to
ethnicity. As revealed by Tukey/Kramer post-hoc comparisons, Caucasian mothers rated the diet
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only treatment significantly lower than AA mothers. The two groups did not differ significantly in
their ratings of no treatment, medication, gene therapy, physical activity, or family lifestyle
change. In addition, the two groups did not differ in their rankings of the treatments. However,
the Caucasian mothers’ rating of gene therapy as being more acceptable than no treatment
approached significance (p =.07).
Maternal weight was also hypothesized to affect treatment ratings (see Hypothesis 2).
However, there were no differences in TEI-sf ratings according to weight status, F(1, 137) =
1.92, p = .10. Neither a main effect of weight nor an interaction of weight by treatment type was
found.
Perceived severity of the problem was predicted to influence acceptability ratings (see Hypothesis
3). A significant main effect for type of problem, F(1, 137) = 6.11, p < .05, was found. Overall,
mothers rated all treatments for T2DM (M = 29.19, SD = 9.97) significantly higher than the same
treatments for obesity (M = 28.09, SD = 10.26). However, this effect is qualified by the
significant interaction between treatment and type of problem, F(5, 137) = 5.42, p < .0001. Table
7 presents the mean TEI-sf scores and standard deviations of the treatments according to the type
of problem. Tukey/Kramer post-hoc comparisons yielded significant differences among the means.
Specifically, mothers in both the Obesity and T2DM groups rated family lifestyle change similarly
to physical activity but significantly more acceptable than the other treatments. In addition, there
was no difference in mothers’ ratings of physical activity and diet in either group. However,
mothers in the Obesity group rated gene therapy and no treatment similarly, but rated both
treatments significantly higher than medication, which was rated the least acceptable as a
treatment for obesity. Mothers in the T2DM group rated gene therapy and medication
significantly higher than no treatment (for T2DM). Figure 1 depicts group mean differences.
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Table 6: Summary of means and standard deviations of TEI-sf, Treatment Type by Ethnicity.
No
treatment

Medication

Gene
therapy

Diet only

Physical
activity

Family
lifestyle

AfricanAmerican
(n=70)

21.07a,b
(7.45)

18.16b
(7.20)

23.47a
(7.49)

35.89c*
(6.01)

36.18c
(4.78)

37.96c
(5.78)

Caucasian
(n=76)

20.30a,b
(6.50)

19.75b
(7.08)

23.34a
(7.30)

33.58c*
(5.13)

35.36c
(5.07)

38.07d
(4.90)

Note: Different superscripts indicate significant differences between Treatments at p < .01.
indicates
significant differences between Ethnicity groups at p < .05.
*
Table 7: Summary of means and standard deviations of TEI-sf, Treatment Type by Type of Problem.

*

No
treatment

Medication

Gene
therapy

Diet only

Physical
activity

Family
lifestyle

Obesity
(n=80)

21.25a
(6.89)

16.53b*
(6.22)

22.50a*
(7.02)

34.96c
(5.98)

35.52c,d
(5.10)

37.75d
(5.32)

Type 2 Diabetes
(n=66)

19.97a
(7.03)

21.97a,b*
(7.12)

24.49b*
(7.67)

34.35c
(5.30)

36.04c,d
(4.74)

38.33d
(5.35)

Note: Different superscripts indicate significant differences between Treatments at p < .01.
indicates significant differences between Type of Problem groups at p < .05.
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Figure 1: Means of TEI-sf scores, Treatment by Type of Problem. * indicates significant difference at p < .05. ** indicates
significant difference at p < .01.
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Weight status, ethnicity, and type of problem were hypothesized to interact to influence
acceptability of the anti-obesity treatments (see Hypothesis 4). However, a significant interaction
of ethnicity, weight status, and problem condition was not obtained, F(1, 137) = 0.25, p = .94.
Translation of TEI-sf Scores into Categorical Groupings
The results of the group analyses can be considered in a more descriptive manner. The
TEI-sf has a total score range of 9 to 45, with each item scored on a 5-point Likert-type scale
(Strongly Disagree/Unacceptable = 1; Neutral = 3; Strongly Agree/Acceptable = 5). If the average
rating of a group is divided by the lowest possible treatment rating (i.e., 9), the rating can then be
translated into a descriptive category. For example, the overall mean of family lifestyle change
was 38.02, significantly higher than all other treatments. When divided by 9, the average family
lifestyle rating becomes 4.22, a score which corresponds with Acceptable for this treatment
option. The descriptive categories are presented in Table 8 and Table 9, showing the treatment
type by ethnicity and treatment type by type of problem interactions, respectively. This descriptive
strategy is further employed in the Discussion section.
Locus of Control
Locus of control was hypothesized to be associated with ratings of treatment acceptability
(see Hypothesis 5). It was expected that higher endorsement of external LOC would be associated
with higher ratings of no treatment, medication, and gene therapy. Hierarchical regression was
used to determine how much of the variance in treatment acceptability ratings could be explained
by LOC after adjustment for background variables, child age, child weight, and level of body
satisfaction. Six regression analyses were conducted to identify predictors of acceptability ratings
at each treatment level. Predictor variables were entered into the analysis in the following order:
(1) background and confounding variables (i.e., ethnicity, maternal BMI, type of problem, total
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Table 8: Summary of translated TEI-sf scores, Treatment Type by Ethnicity.
No
treatment

Medication

Gene
therapy

AfricanAmerican
(n=70)
Caucasian
(n=76)

Diet only

Physical
activity

Family
lifestyle

2.34
(U-N)

2.02
(U)

2.61
(N)

3.99
(A)

4.02
(A)

4.22
(A)

2.26
(U-N)

2.19
(U)

2.59
(N)

3.73
(N-A)

3.93
(A)

4.23
(A)

Note: Each original mean was divided by 9, the lowest possible acceptability rating on the TEI-sf. SA = Strongly Acceptable; A
= Acceptable; N = Neutral; U = Unacceptable; SU = Strongly Unacceptable.
Table 9: Summary of translated TEI-sf scores, Treatment Type by Type of Problem.
No
treatment

Medication

Gene
therapy

Obesity
(n=80)
Type 2 Diabetes
(n=66)

Diet only

Physical
activity

Family
lifestyle

2.36
(U-N)

1.84
(SU-U)

2.50
(U-N)

3.88
(N-A)

3.95
(A)

4.19
(A)

2.22
(U)

2.44
(U-N)

2.72
(U-N)

3.82
(N-A)

4.00
(A)

4.26
(A)

Note: Each original mean was divided by 9, the lowest possible acceptability rating on the TEI-sf. SA = Strongly Acceptable; A
= Acceptable; N = Neutral; U = Unacceptable; SU = Strongly Unacceptable.
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annual income, child age); (2) total score on the BSQ; and (3) LOC scores (i.e., WLOC total;
MHLC-Internal subscale; MHLC-Chance subscale; MHLC-Powerful Others subscale).
At each step, all indicators for each predictor variable were entered simultaneously into
the model. The total TEI-sf score for each type of treatment was entered as the criterion variable.
Background variables and BSQ scores were entered first into the model to remove potential
confounding effects of such variables on acceptability ratings.3 Square root transformations were
used on total annual income and maternal BMI due to their moderate levels of negative skewness
(Tabachnick & Fidell, 2001). With the use of a p < .001 criterion for Mahalanobis distance, no
outliers among the cases were identified. No cases had missing data and no suppressor variables
were identified, N = 146. At each step, the contribution to the model of (a) each individual
indicator (shown by the individual p-value), and (b) the class of predictor as a whole (shown by
the change in R2) was examined.
No individual or class variables were found to significantly correlate with acceptability
ratings of gene therapy, diet alone, physical activity, and family lifestyle change. However,
acceptability ratings of medication and no treatment were found to have significant correlates.
Results from the hierarchical regression assessing correlates of medication acceptability ratings
are outlined in Table 10. At step 1, the background variables were entered into the equation, R2 =
.19, adjusted R2 = .16, F(5, 134) = 6.34, p < .0001, explaining 16% of the variance in
acceptability ratings for medication. Of the variables entered, the type of problem (i.e., Obesity,
T2DM) and the square root of maternal BMI were significantly associated with treatment
acceptability ratings for medication. At step 2, the total score on the BSQ was entered into the
regression model, R2 = .19, adjusted R2 = .15, F(1, 134) = 0.31. Addition of BSQ total score to
the equation with background variables did not result in a significant increment in R2 (i.e.,
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explained variance remained at 19%). Locus of control measures were added at step 3, R2 = .20,
F(4, 134) = 0.62. Addition of LOC to the equation did not reliably improve R2 and none of the
variables were individually associated with medication acceptability ratings. After step 3, with all
IVs in the equation, R = .45, R2 = .20, adjusted R2 = .14, F(10, 134) = 3.40, p < .001, explaining
14% of the variance in medication acceptability ratings.
Only the type of problem remained individually associated with acceptability ratings of
medication at all steps. In this model, the Obesity condition was assigned a value of 1 and the
T2DM problem was assigned a value of 2. Therefore, the positive relationship between type of
problem and acceptability ratings, as indicated by β = 0.39, suggested that increased disease risk
(i.e., T2DM) was associated with higher acceptability ratings for medication.
Results from the hierarchical regression assessing predictors of acceptability ratings for the
no treatment option are outlined in Table 11. The regression analysis did not reach significance at
p < .05 – however, the predictor class at step 1 reached p = .53 and two individual indicators
reached significance within predictor classes. Therefore, the results of this regression analysis are
described to explore possible correlates of the acceptability of the no treatment option. At step 1,
the background variables were entered into the equation, R2 = .08, adjusted R2 = .04, F(5, 134) =
2.25, p =.053, explaining only 4% of the variance in acceptability ratings for the no treatment
option. Of the variables entered, target child age was significantly associated with treatment
acceptability ratings for no treatment – older child age predicted lower acceptability ratings for no
treatment. At step 2, the total score on the BSQ was entered into the prediction equation, R2 =
.08, adjusted R2 = .04, F(1, 134) = 0.03. Addition of BSQ total score to the equation with
background variables did not result in a significant increase in R2 (i.e., explained variance
remained at 4%). LOC measures were added at step 3, R2 = .11, adjusted R2 = .05, F(4, 134) =
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Table 10: Hierarchical regression predicting acceptability ratings of medication.
Variables entered
Step 1: background variables
Ethnicity
Type of problem
Maternal BMI
(square root transformation)
Total annual income
(square root transformation)
Target child age
Step 2: body dissatisfaction
BSQ-sf total score
Step 3: locus of control
WLOC
MHLC-I
MHLC-C
MHLC-PO

p-value at
entry

R2

ΔR2

F-test for ΔR2

d.f.

p-value for
ΔR2

0.19

0.19

6.34

5

0.0001

0.19

0.002

0.31

1

0.58

0.20

0.02

0.62

4

0.65

0.42
0.0001
0.02
0.28
0.57

0.58

0.56
0.87
0.21
0.66

Note: BMI = body mass index; BSQ-sf = Body Shape Questionnaire – short form; WLOC = Weight Locus of Control Scale;
MHLC-I = Multidimensional Health Locus of Control Scale – Internal subscale; MHLC-C = Multidimensional Health Locus of Control
Scale – Chance subscale; MHLC-PO = Multidimensional Health Locus of Control Scale – Powerful Others subscale.
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Table 11: Hierarchical regression predicting acceptability ratings of no treatment.
Variables entered
Step 1: background variables
Ethnicity
Type of problem
Maternal BMI
(square root transformation)
Total annual income
(square root transformation)
Target child age
Step 2: body dissatisfaction
BSQ-sf total score
Step 3: locus of control
WLOC
MHLC-I
MHLC-C
MHLC-PO

p-value at
entry

R2

ΔR2

F-test for ΔR2

d.f.

p-value for
ΔR2

0.08

0.08

2.25

5

0.053

0.08

0.00

0.03

1

0.87

0.11

0.04

1.42

4

0.23

0.57
0.15
0.35
0.57
0.01

0.87

0.46
0.05
0.99
0.44

Note: BMI = body mass index; BSQ-sf = Body Shape Questionnaire – short form; WLOC = Weight Locus of Control Scale; MHLC-I
= Multidimensional Health Locus of Control Scale – Internal subscale; MHLC-C = Multidimensional Health Locus of Control Scale –
Chance subscale; MHLC-PO = Multidimensional Health Locus of Control Scale – Powerful Others subscale.
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1.42. Addition of LOC to the equation did not reliably improve R2. Of the variables entered, the
MHLC-Internal subscale was significantly associated with acceptability ratings for no treatment –
higher levels of internal LOC predicted lower acceptability ratings of no treatment. After step 3,
with all IVs in the equation, R = .34, R2 = .11, adjusted R2 = .05, F(10, 134) = 1.70, p = .09,
explaining only 5% of the variance in acceptability ratings.
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Discussion
The primary aim of the current study was to evaluate the impact of hypothetical genetic
knowledge on treatment acceptability in the prevention of obesity and T2DM, attempting to
partially answer Ridley’s (1999) question of how genetic information affects planning for the
future. Because ethnicity and parental weight have been shown to influence the “success” of
pediatric anti-obesity/T2DM treatments, these factors were hypothesized to differentially affect
the acceptability of the preventive treatments, potentially influencing the outcomes of prevention
efforts. The following discussion of the results is organized according to the five hypotheses of
the study. In addition, a discussion of the rankings of the preventive treatments is provided.
Finally, limitations of the current study are discussed and suggestions for future research are
provided.
Hypotheses and Treatment Rankings
Hypothesis 1. Ethnic background of the raters was hypothesized to influence treatment
acceptability ratings. Although AA mothers endorsed higher levels of body satisfaction than
Caucasian mothers, they did not rate anti-obesity treatments for their children lower than
Caucasian mothers. The most probable explanation for this finding is that endorsement of higher
levels of body satisfaction does not negate the knowledge of and concern for the health and
psychosocial consequences of obesity. The higher levels of body satisfaction may simply weaken
the urgency with which to engage in prevention strategies over the long-term, undermining the
overall success of obesity prevention programs but not necessarily the acceptability of those same
programs.
The findings suggest that AA mothers were more willing than Caucasian mothers to
consider diet modification as a prevention strategy. It is possible that recent efforts to promote
52

lifestyle changes within the AA community have increased exposure to and, thus, acceptance of
dietary changes (Kumanyika, 2002). Although statistically significant, the difference between the
ethnicity groups might not be practically meaningful. The AA mothers rated diet in the Acceptable
range, whereas Caucasian mothers rated diet only slightly lower in the Neutral-Acceptable range.
In addition, diet was as acceptable as physical activity and lifestyle change for the AA mothers and
only slightly less acceptable than those treatments for the Caucasian mothers. That is, the diet
option for both groups was still ranked well above the remaining treatment options of gene
therapy, medication, and no treatment. Therefore, the difference might not be practically
significant.
Hypothesis 2. Maternal weight was hypothesized to influence treatment acceptability
ratings – when compared with Overweight mothers, the Normal-weight mothers were predicted
to rate the behaviorally oriented treatments as more acceptable. However, results indicated that
body weight status of the parent was not a significant factor associated with treatment
acceptability. Examination of the means revealed that the ratings of the behavioral treatments (i.e.,
family lifestyle, physical activity, diet) were almost exactly the same between the two weight
groups. The finding that both weight groups found the behaviorally-oriented treatments similarly
acceptable is understandable – lifestyle changes in diet and/or physical activity seem to be
generally viewed as ‘healthy,’ as evidenced by the high ratings of the behavioral treatments
overall.
Hypothesis 3. Acceptability ratings were strongly influenced by the type of problem
presented in the case description. As predicted, mothers rated treatments for T2DM as more
acceptable than treatments for obesity. In addition, the more intrusive gene therapy and
medication treatments were considered more acceptable for T2DM than for obesity. However, the
53

behavioral methods were still ranked well above the more intrusive treatments, suggesting that
although mothers do not consider the intrusive treatments as acceptable, they are more willing to
consider them as treatment alternatives in light of increased disease risk for their children. This
trend is supported by previous findings that preference for all treatments and the acceptability of
more intrusive treatments seem to vary as a function of problem severity (Calvert & Johnson,
1990; Tarnowski et al., 1989).
These findings have direct implications for recommendations related to treatment delivery
by health-care providers. Because T2DM is considered a consequence of obesity (Pinhas-Heimel
& Zeitler, 2000), recommendations might need to emphasize the health consequences of obesity.
The lower preventive acceptability ratings shown in the current study suggest that obesity alone
does not have the disease and perceived risk status of diabetes. The case description in the current
study provided both the health and social consequences of obesity, but did not focus on one over
the other. Further investigation is needed to determine if emphasis of the physical complications of
pediatric obesity increases acceptability ratings and, potentially, implementation of prevention
strategies.
Hypothesis 4. Ethnicity, maternal weight, and type of problem were all expected to
interact to influence acceptability ratings – Caucasian mothers were predicted to rate anti-obesity
treatments as more acceptable than AA mothers, presumably due to lower levels of body
satisfaction. In addition, Overweight AA mothers were expected to provide the lowest ratings of
anti-obesity treatments (again, due to higher levels of body satisfaction at higher weights). Ratings
of T2DM treatments were not expected to differ. Results indicated no significant differences in
acceptability ratings among the groups.
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The previous findings might augment the failure to find significant differences among the
ethnicity and weight groups. As discussed, there were no differences in anti-obesity treatment
ratings between the ethnic groups. Higher levels of body satisfaction did not translate into lower
treatment acceptability ratings for obesity. In addition, the weight status groups did not differ in
their ratings of the preventive treatments – Overweight and Normal-weight mothers rated the
various treatments similarly. A possible explanation echoes the previous rationale: mothers tend to
find behavioral lifestyle methods that include changes in diet and/or physical activity as ‘healthy’
and, therefore, as highly acceptable. This possibility is further discussed in the next section of
general treatment rankings.
Hypothesis 5. It has been suggested that the increased ‘geneticization’ of society might
lead to an increased fatalism (i.e., external LOC) about health, which could undermine prevention
efforts (Hunt, Davison, Emslie, & Ford, 2000). Therefore, LOC was hypothesized to be
associated with acceptability of prevention strategies, with high endorsement of external LOC
expected to predict higher acceptability ratings of no treatment, medication, and gene therapy.
Findings did not support this hypothesis – in general, LOC was not significantly correlated with
preventive treatment acceptability ratings. In addition, the analysis did not identify any variables
that were significantly associated with the behavioral interventions or gene therapy.
The lack of an association between external LOC and preventive treatment acceptability is
interesting. Locus of control has been posited as a factor in the search for and use of healthrelated behaviors (Norman et al., 1998). Fatalism, defined by the belief in an external LOC, has
been linked with decreased preventive behaviors, such as cancer screening, condom use, cessation
of cigarette use, and HIV-antibody testing and treatment (Carey, Gordon, Morrison-Beedy, &
McLean, 1997; Facione, Miaskowski, Dood, & Paul, 2002; Foss, 1973; Hardeman, Pierro, &
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Mannetti, 1997; Mayo, Ureda, & Parker, 2001). It is possible that the specific measurement of
health-related LOC in the current study was too restrictive; a more general measure of LOC (e.g.,
Rotter’s Generalized Internal-External LOC Scale, Powe Fatalism Inventory) might reveal
associations between LOC and acceptability ratings.
It is also possible that treatment acceptability and LOC are not directly related. For
example, individuals, regardless of LOC, might find preventive strategies as highly acceptable.
However, LOC might moderate the adoption of those preventive strategies. The finding that
higher levels of internal LOC (as an individual indicator) predicted lower acceptability ratings of
no treatment seems to support this possibility. Endorsement of a higher level of internal LOC
might have decreased the acceptability of no preventive action at all, implying that some form of
preventive action would be considered acceptable. However, LOC was not found to be associated
with acceptability ratings for any form of preventive strategy in this study. Further research is
needed to explore the relationship among LOC, the acceptability of prevention interventions, and
the use of the interventions.
The hierarchical regression revealed two additional predictors of treatment acceptability.
First, the type of problem was associated with medication acceptability ratings. Increased risk of
disease (as defined by the type of problem) was correlated with higher levels of medication
acceptance. This finding is supported by previous findings of increased acceptance of intrusive
treatments for more severe conditions (Calvert & Johnson, 1990). Second, child age predicted
acceptability ratings of the no treatment option: older child age predicted lower acceptability
ratings for no treatment and, conversely, younger child age predicted higher ‘no treatment’
acceptability ratings. These results suggest that as their children age, mothers increasingly rate
some form of preventive action as acceptable. It is possible that when children are younger,
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mothers remain optimistic about their children’s health potential; as the children grow, this
optimism might weaken, with a consequent acceptance of some form of preventive action.
However, child age was not associated with any form of preventive strategy presented in the
current study. In addition, no published reports of child age as a factor in prevention strategies
were found to support this possibility, indicating that further exploration is necessary. Specifically,
the finding that younger child age predicts higher acceptability of no treatment is extremely
important in the prevention of obesity and T2DM. Research has shown that the prevention of
obesity and T2DM should begin in children as young as two years old (Barlow & Dietz, 1998). If
parents with younger children are more willing to consider not treating their children (until the
children age), prevention efforts will be ineffective.
General Treatment Rankings. Comparisons of within-group ratings revealed some
interesting findings – the rankings of the treatments varied slightly according to the different
groupings. Overall, mothers found the behavioral treatments the most acceptable, with family
lifestyle change the most preferred treatment option (categorically rated as Acceptable-Strongly
Acceptable). The preference for some form of lifestyle change remained consistent in all the
groups. These findings are understandable –behavioral treatments that include some form of
dietary change and/or physical activity define many commercial weight-loss programs (Womble,
Wang, & Wadden, 2002). The changes involved are also typically considered part of a ‘healthy’
lifestyle. Within the framework of general treatment acceptability research, the behavioral
prevention strategies seem to be consistent with consumer expectations of what antiobesity/T2DM treatments should entail (Kazdin, 1980a).
This pattern of acceptability is encouraging in that the more lifestyle-oriented treatments
are generally well researched and are promoted as first-line preventive strategies. Treatment
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acceptability has been shown to be related to intervention usage, adherence, and outcome
(Reimers et al., 1992b). Specifically, TA appears to be involved in the mediation of negative
clinical outcomes, including treatment termination, nonadherence, and lack of improvement
(Calvert & Johnson, 1990; Elliott, 1988; Reimers et al., 1992b; Tarnowski et al., 1992).
Relatively strong acceptance of the behavioral interventions that include diet and/or physical
activity would suggest longer implementation of and adherence to these strategies. However,
treatment effects tend to be more stable in children than in adolescents. Early termination of and
nonadherence to interventions are evidenced by the modest findings of weight loss studies in
adolescents, suggesting that child age might be an additional factor influencing treatment
acceptability.
The no treatment option and the more intrusive treatments did not seem to fit with the
conventional notions of prevention for any of the groups. All three strategies were ranked well
below the behavioral methods in all groups, categorically ranging from Strongly Unacceptable to
Neutral. It is important to note that the current study is the first to include a no treatment option
in an investigation of treatment acceptability. The low ratings (and rankings) of this option
indicate that mothers did not consider this a viable alternative; mothers seem to prefer some form
of lifestyle action if told that their children are at risk for obesity or T2DM. However, the relative
group rankings were surprising. Mothers rated gene therapy just as acceptable as not treating their
children and as more acceptable than medication. They preferred medication to not treating their
children only when a more serious health problem (i.e., T2DM) was considered.
These findings lend support to the trend seen in previous TA research – mothers might be
more willing to consider more intrusive and radical treatments if the risk to their children is
increased. Previous research has found that treatments are generally more acceptable when
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applied to more severe behavior and health problems (Calvert & Johnson, 1990; Elliott, 1988;
Frentz & Kelley, 1986; Kazdin, 1980a; Reimers & Lee, 1991). In addition, the acceptability of
more intrusive treatments has been shown to vary as a function of problem severity (Tarnowski et
al., 1989). For example, Reimers and Lee (1991) found that medication was rated by parents as
relatively more acceptable when applied to a more severe health problem as opposed to a mild
problem.
The suggestion that a more intrusive and radical treatment such as gene therapy would be
considered acceptable over the more traditional medication treatment is an unexpected finding.
Genetic research has been gaining momentum, funding, and media exposure over the past several
years. Although actual research findings are still preliminary, the media has suggested the
numerous possibilities that will be available when gene therapy has more fully progressed (e.g.,
Rowland, 2000). Perhaps these reports (and their increasing frequency) have influenced maternal
ratings of this treatment alternative. Gene therapy might also be considered a ‘permanent’ and
effective solution, requiring little time and effort in the long-term (as depicted in the treatment
description). These considerations might have increased acceptability over medication, an
alternative that requires daily effort to maintain its effect. Further investigation is needed to
determine if new research findings and decreased perceived risks in treatment might increase
preference for gene therapy as a prevention alternative.
Preliminary investigation of direct-to-consumer (DTC) advertising of prescription
medications suggests that it is possible to alter consumer perception of the more intrusive
treatments. In 1997, the Federal Drug Administration issued guidelines for the broadcast
advertising of prescription drugs directly to consumers. Subsequently, annual spending on DTC
advertising tripled between 1996 and 2000, when it reached nearly $2.5 billion (Rosenthal,
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Berndt, Donohue, Frank, & Epstein, 2002). Recent national and clinic-based surveys suggest that
DTC advertising has increased consumer awareness of disease symptoms and specific medications
and that this awareness is associated with specific medication requests made to physicians
(Meade-D’Alisera, Merriweather, & Wentland, 2001; U.S. Food and Drug Administration, 2002).
The increase in DTC advertising is also associated with a rise in sales figures. Total US drug
expenditures increased by almost 19% from 1998 to 1999. Prescriptions for the top 25
medications directly marketed to consumers rose by 34% during this time, compared with 5.1%
for all other prescription drugs (Charatan, 2000).
Content analyses indicate that the DTC advertisements appeal to emotions and address the
variables that constitute the treatment acceptability construct: effectiveness, ease of use,
safety/side effects, and benefits/psychosocial enhancement (Bell, Kravitz, & Wilkes, 2000;
Woloshin, Schartz, Tremmel, & Welch, 2001). In other words, pharmaceutical companies have
increased consumer demand for and purchase of prescription medications by focusing on the
factors associated with treatment acceptability. These data suggest that this marketing strategy
could influence the demand for (i.e., acceptance of) new medications and gene therapy for the
prevention of obesity and T2DM. This possibility bears further investigation.
Limitations of the Current Study
It should be noted that the present study is subject to the limitations inherent in analogue
investigations. First, the generalizability of these findings to clinic populations remains unknown,
that is, generalizing from potential clients to actual clients (Pickering, Morgan, Houts, &
Rodriguez, 1988). Second, the ecological validity of the independent variables used in TA
research has been questioned (Elliott, 1988). The case and treatment descriptions used in previous
TA research and in the current study contained minimal information. In actual situations where
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consumers (e.g., parents) are faced with a choice among treatments, much more information is
typically available concerning both the case and treatment plans. Although analogue investigations
permit the study of multiple independent variables in a highly controlled manner, there is need to
obtain data in the context of applied service delivery. However, this direct test of acceptability is
difficult to accomplish for a variety of practical and ethical reasons. For example, one cannot
reasonably ask parents to provide acceptability ratings before their child is treated, and then
provide a treatment that the parents judged to be unacceptable. Retrospective ratings are also
problematic in that treatment ratings might be confounded by case-specific outcomes, therapist
variables, and patient selection factors. Thus, analogue methods provide a cost-effective and
viable method for the preliminary identification of variables that influence treatment acceptability.
The generalizability of the findings may also have been limited due to the difficulty in
recruitment of normal-weight females. Although there were over 7000 potential participants in the
PBRC database who met inclusion criteria, only 3% were AA females and 14% were Caucasian
females who were within the normal BMI range at the time of initial contact. PBRC is a nonprofit research institution devoted to nutrition and preventive medicine research – its primary
research tracks focus on obesity, nutrition and chronic disease, and health and performance
enhancement. As such, the majority of the database participants have BMIs of 25 kg/m2 and
above. To remedy this problem, a recruitment effort focused on normal-weight females by mailing
a higher percentage of packets to those subjects; however, many of those who returned completed
packets from this mail-out had gained weight in the interim (from time of initial contact to the
current contact) to BMIs above the normal range. This weight gain, combined with incorrect
addresses, indications of no children, and children outside the specified age range of 2-17 years,
resulted in too few normal-weight AA females (see Table 1). Post-hoc power analysis also
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revealed that a small effect size of 0.30 SD could be detected with 67% power; that is, the low
number of normal-weight AA females might have resulted in a decreased ability to detect the
interaction among ethnicity, weight status, and type of problem. However, in the current study,
such a small effect size might be practically meaningless. The power analysis also indicated that
there were a sufficient number of participants to detect a large effect size of 1.00 SD with 92%
power. The lack of a significant interaction, with sufficient power to detect a large difference,
might actually indicate the ‘true’ and meaningful finding.
Future Directions
Despite these limitations, the current study provides the groundwork for a new line of
research in the prevention of obesity and T2DM. Overall findings suggested that mothers
generally considered lifestyle changes that involve diet and/or physical activity as acceptable
treatments for their children. However, the limited success of the behavioral strategies with
adolescents and the identification of child age as a predictor of ‘no treatment’ acceptability
demand further examination.
Although maternal weight did not have the expected effects on acceptability ratings, slight
trends in the data suggested that a history of higher weight might increase acceptability of the
more intrusive preventive treatments. That is, prior experience with the problem condition might
influence treatment acceptability. Future studies should examine the effect of different problem
histories (e.g., presence or absence of T2DM) on treatment acceptability. Prior history might alter
acceptance of preventive treatments.
Gene therapy and no treatment were consistently rated as more acceptable than
medication, unless disease risk was increased. However, all three alternatives were consistently
ranked as unacceptable treatments. Future research should investigate the effect of an increased
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genetic probability of developing a problem (e.g., 20% v. 80%). Increased genetic risk might
influence the acceptance of the more intrusive preventive strategies, potentially increasing them to
acceptable levels. Direct-to-consumer marketing strategies might also influence preference for
these alternatives. An examination of the social and ethical ramifications of these possibilities are
necessary with the increasing societal focus on genetic predisposition.
Another area of future research involves parent gender. Most treatment acceptability
studies have included only mothers as potential consumers. However, in many cases, both parents
would be involved in preventive treatment decisions for their child. In addition, early treatment
acceptability research indicates that males tend to favor more intrusive/medical treatments over
less intrusive treatments (Miller & Kelley, 1992). This finding suggests that inclusion of fathers in
future studies is warranted.
General Conclusions
In summary, the current study used a novel approach to identify the acceptability of
treatments designed to prevent the occurrence of obesity and T2DM. Identification of variables
that are related to obesity/T2DM prevention acceptability is necessary if future prevention efforts
are to succeed. The possibility that gene therapy will someday be developed to counter the
development of obesity and/or T2DM demands investigation of the acceptability of prevention
efforts in response to genetic testing. In the present study, acceptability ratings varied according
to treatment type and type of problem (i.e., genetic predisposition to obesity or T2DM). General
findings suggest that mothers found the lifestyle strategies as acceptable preventive interventions,
whereas they considered the medical/intrusive strategies (and no treatment at all) as unacceptable
alternatives. Heightened disease risk increased acceptability for all forms of treatment, specifically
medication. However, gene therapy was generally ranked as more acceptable than medication,
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suggesting that mothers might consider this treatment option in lieu of medication when more
intrusive strategies are preferred and/or recommended. Advertising efforts on the part of
pharmaceutical companies may further increase the acceptance and preference for these
alternatives. These findings provide the groundwork for future investigations on the variables that
influence treatment acceptability in response to genetic information.
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Endnotes
1

Body mass index (BMI) is considered a measure of adiposity based on height and weight
(kg/m2). Among the height-weight indices available for study, BMI has been shown to be a
satisfactory index of overweight associated with adiposity. Overweight and obesity in adults are
defined as follows: Overweight (BMI  25); pre-obesity (BMI 25.0 – 29.9); class I obesity (BMI
30.0 – 34.9); class II obesity (BMI 34.9 – 39.9); class III obesity (BMI  40.0). For children and
adolescents, BMI values above the 95th percentile are considered obese/overweight whereas
values between the 85th and 95th percentiles are considered ‘at-risk’ for becoming overweight
(Troiano & Flegal, 1998). However, some researchers consider BMI values at or above the 85th
percentile as indicative of obesity.
2

The Overweight/Obese group (M = 4.02, SD = 7.50) also reported a significantly higher number
of previous diets than the Normal weight group (M = 1.69, SD = 2.44), F(1, 95) = 4.33, p < 0.05.
However, 50 participants did not report the number of previous diets, indicating that there were
“too many” diets to remember/count.
3

Child BMI and number of previous diets were not included as predictor variables due to
extensive missing data (n = 27 and n = 50, respectively).
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Appendix A
Procedural Question

One last question!!
The researchers would like to know your perception of the study.
Which one of the following fits what you were supposed to do for this study?
___

I answered the questions as if my child were answering the questions.

___

I answered the questions according to what my child would be willing to do and would
want to do, not what I would do.

___

I imagined my child in the Story and rated the approaches/treatments for what I would be
willing to do for that child.

___

I answered the questions how I thought the researchers would want me to.

___

I rated the treatments for how I thought other parents would rate the treatments, not what
I would do.

___

I answered the questions according to what my child’s father and I would be willing to do
for our child.

___

Other
Please explain: __________________________________________________________
________________________________________________________________________
________________________________________________________________________

You’re done!!
Please be aware that Gene Therapy is not available for obesity or diabetes at this time. It is a
possible future treatment. Pennington does not offer or conduct this type of treatment.

Thank you!!!
We would like to thank you for participating in this study. All you need to do now is return
everything in the pre-paid envelope. We appreciate you for taking the time to fill out the
questionnaires!
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Appendix B
Demographic Questionnaire
Your Date of Birth: _________________

Age: _____________

Occupation: _______________________
Sex:

___ Male
___ Female

Height: ______feet _______inches
Marital Status:

Weight: _________lbs.

___ Single

___ Married

___ Divorced

___ Separated

___ Widowed
Race:

___ Black

___ Asian

___ White
___ Hispanic origin

___ American Indian, Aleutian, Alaska
native, or Eskimo

___ American Indian, Aleutian, Alaska native, or Eskimo
___ Other (please specify: _________________________)
Have you ever been diagnosed with the following?
___ Type 2 diabetes
___ Heart disease
___ Other (please specify: _________________________)
Does anyone in your family suffer from the following?
___ Type 2 diabetes (if so, who in your family? ______________________)
___ Heart disease (if so, who? ______________________)
___ Other (please specify: _________________________)
Circle the number of years of formal education that you have completed. (please include all
grade school, high school, and college/vocational years)
0

1

2

3

4

5

6

7

8

13

14

15

16

17

18

20

21+
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9

10

11

12

What is the total annual income of your household? ____________________dollars per year.
Have you ever been on a diet previously? ___ Yes

___ No

If yes, how many times? _____________
Have you ever participated in a study conducted by PBRC? ___ Yes ___ No
Please answer the following questions according to your Oldest (or Youngest) child between
the ages of 2 and 17 years.
Sex of child:

___ Male

Age of child: ________

___ Female

Date of birth: ___________

Child height: ______feet _______inches

Child weight: _________lbs.

Has your child ever been diagnosed with diabetes?
____ Yes

____ No

If yes, what type of diabetes has your child been diagnosed with?
____ Type 1 diabetes
____ Type 2 diabetes
____ Not sure
If yes, at what age was your child diagnosed with diabetes? _________ years
How much experience do you have with health care services for your child?
1
Significantly
below average

2
Below
average

3

4

Average
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Above
average

5
Significantly
above average

Appendix C
Body Shape Questionnaire – Short Form
We would like to know how you have been feeling about your appearance over the PAST FOUR
WEEKS. Please read each question and circle the appropriate number. Please answer all the
questions.
1 = Never
2 = Rarely
3 = Sometimes
4 = Often
5 = Very Often
6 = Always
____ 1.

Have you worried about your flesh not being firm enough?

____ 2.

Have you noticed the shape of other men/women and felt that your own shape
compared unfavorably?

____ 3.

Have you avoided wearing clothes which make you particularly aware of the
shape of your body?

____ 4.

Have you felt ashamed of your body?

____ 5.

Has worry about your shape made you diet?

____ 6.

Have you felt happiest about your shape when your stomach has been empty
(e.g., in the morning)?

____ 7.

Have you felt that it is not fair that other men/women are thinner than you?

____ 8.

Have you worried about your flesh being dimply?
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Appendix D
Weight Locus of Control
Please complete the items listed below by circling the number that best indicates how you feel.

1. Whether I gain, lose, or maintain
my weight is entirely up to me.

Strongly
Disagree

Disagree

Slightly
Disagree

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

2. Being the right weight is largely a
matter of good fortune.

1

2

3

4

5

6

3. No matter what I intend to do, if I
gain or lose weight, or stay the same
in the near future, it is just going to
happen.

1

2

3

4

5

6

4. If I eat properly, and get enough
exercise and rest, I can control my
weight in the way I desire.

1

2

3

4

5

6
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Appendix E
MHLC Scale
Please complete the items listed below by circling the number that best indicates how you feel.

1. If I become sick, I have the power
to make myself well again.

Strongly
Disagree

Disagree

Slightly
Disagree

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

2. Often I feel that no matter what I do,
if I am going to get sick,
I will get sick.

1

2

3

4

5

6

3. If I see an excellent doctor regularly,
I am less likely to have health
problems.

1

2

3

4

5

6

4. It seems that my health is greatly
influenced by accidental happenings.

1

2

3

4

5

6

5. I can only maintain my health by
consulting health professionals.

1

2

3

4

5

6

6. I am directly responsible for my
health.

1

2

3

4

5

6

7. Other people play a big part in whether
I stay healthy or become sick.
1

2

3

4

5

6

8. Whatever goes wrong with my health
is my own fault.

1

2

3

4

5

6

9. When I am sick, I just have to let
nature run its course.

1

2

3

4

5

6

10. Health professionals keep me healthy.

1

2

3

4

5

6

11. When I stay healthy, I’m just plain
lucky.

1

2

3

4

5

6

12. My physical well-being depends on
how well I take care of myself.

1

2

3

4

5

6
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13. When I feel ill, I know it is because I
have not been taking care of myself
properly.

Strongly
Disagree

Disagree

Slightly
Disagree

Slightly
Agree

Agree

Strongly
Agree

1

2

3

4

5

6

14. The type of care I receive from
other people is what is responsible
for how well I recover from
an illness.

1

2

3

4

5

6

15. Even when I take care of myself,
it’s easy to get sick.

1

2

3

4

5

6

16. When I become ill, it’s a matter
of fate..

1

2

3

4

5

6

17. I can pretty much stay healthy by
taking care of myself.

1

2

3

4

5

6

18. Following doctor’s orders to the
letter is the best way for me to
stay healthy.

1

2

3

4

5

6
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Appendix F
Participant Instructions
On the next page, you will read about some recent scientific discoveries and how these
discoveries could affect parents like you. When reading the story, imagine that it is about you
and your Oldest/Youngest child between the ages 2 to 17 years old. After you read each
story, you will be asked several questions. Please do not look ahead or look back in the
packet. Please answer the questions in the order in which they are given. Also, please call Jean
Thaw at 763-3111 for help if you do not understand what you should do or if you have trouble
with any of the questions. Thank you.
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Appendix G
Introduction
After ten years of study, scientists have identified all of the genes that make up the human
body. Genes are in every cell of our bodies. They cause height, hair color, and eye color. They
also can cause us to be more likely to get certain illnesses, like diabetes or cancer. In the next few
years, scientists will know what each gene does. They will know which genes cause eye color,
which genes cause height, and which genes cause cancer. Knowing what the genes do will change
the medical field forever. Scientists will be able to make medicines that will attack only the
illness, leaving the rest of the body alone. And, doctors will be able to tell if someone is more
likely to get sick, such as with diabetes, before the person actually gets sick. However, it is up to
people to decide what to do with the information. Sometimes, parents will be asked to decide if
anything should be done to stop the illness from happening to their children. These questions may
be hard for parents to answer.
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Case Description
We would like you to imagine yourself in the following story and answer questions about each of
the different approaches that follow the story. You should imagine that the child is your
Oldest/Youngest child between the ages of 2 to 17 years old. Please answer the questions in
the order in which they are given.
Case Description (diabetes):
Your child’s genes have been tested. The doctor told you that your child is likely to get
Type 2 diabetes during the next 10 to 40 years, unless you do something to prevent it. Type 2
diabetes is a disease in which the body “forgets” how to break down food. When this happens,
there is too much sugar in the blood for too long. Over time, this causes many serious health
problems, even if the disease is treated. If Type 2 diabetes develops, your child will feel tired and
weak and will become sick more often. Cuts, burns, and scrapes will take longer to heal. Your
child’s eyesight may get worse until, after many years, he/she could go blind. Your child may
have some heart problems. The blood vessels may become more and more blocked, until he/she
has a heart attack as a young adult. Your child’s kidneys may stop working properly, and your
child might need a kidney machine or a kidney transplant. Over time, your child might lose feeling
in his/her feet, which could result in foot sores or a foot amputation. As an adult, pregnancy and
having a child will be more difficult. However, you can choose among several treatments that will
be paid by a third-party to prevent diabetes and these other problems.
Case Description (obesity):
Your child’s genes have been tested. The doctor told you that your child is likely to
become obese during the next 10 to 40 years, unless you do something to stop it. Obese means
that someone is very heavy or weighs too much. If your child gains too much weight during the
next few years, he/she will likely be obese as an adult. Being obese has many serious risks. Your
child may have high blood pressure and heart disease, leading to a heart attack as a young adult.
Your child will be more likely to get cancer and develop diabetes. Other people may tease your
child because of his/her weight. Your child may have a low self-esteem and problems making
friends. Even if your child is able to lose the weight when he/she is an adult, many of the health
problems may still happen if your child becomes obese before he/she grows up. Also, your child
will be less likely to go to college and marry someone if he/she is obese as a child or teenager. As
an adult, an obese person is less likely to get raises at his/her job and is less likely to marry.
However, you can choose among several treatments that will be paid by a third-party to stop your
child from gaining too much weight and having these problems.
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Appendix H
Treatment Descriptions
Note: Treatment titles were not included in the study materials.
No Change
Because the doctor told you that your child only has a chance of getting diabetes, you
choose to do nothing different. You pay no attention to the information. You raise your child as
you have been doing. Your child plays inside and outside as much as he/she has always done.
There is no change in the amount of time spent watching TV or playing sports. You do not
change the foods that you feed your child. Your child eats what he/she has been always been
eating at school. Your child does not take any new medicine, except for what he/she usually
takes. You allow your child to do what he/she enjoys as much as you have always done. You
bring your child to the doctor as much as you have always done. You raise your child as you
have always done. The possibility that your child could get diabetes is not changed.
Physical Activity Alone
To stop your child from getting diabetes, you decide to improve your child’s health and
fitness. At the beginning of treatment, you and your child attend a 1-hour class every week for 10
weeks. Your child is able to do things he/she enjoys if he/she is active or works out at least 3-4
times a week. Being active can be swimming, walking quickly around the block, riding a bicycle,
and playing in sports (such as basketball or tennis). You praise your child when he/she is
physically active instead of watching TV or playing video games. You encourage your child to
play sports. When your child chooses to play sports or do something active at least 3-4 times in a
week, your child gets to go to the movies or go to a party or do something he/she enjoys (but is
something that you both agree on). It could be hard to get your child to be active if he/she does
not want to be active. It takes time to encourage and teach your child to be active. Your child
might get hurt if the physical activity is not safe or if he/she does too much at once.
Medication (Sibutramine/Meridia)
The doctor gives your child medicine to keep him/her from becoming obese. The
medicine will help your child eat less every day. You give your child a pill every morning at
breakfast. You will also bring your child back to the doctor for a check-up about every three
months. The medicine can cause your child to have a dry mouth or have a hard time falling
asleep. Your child may have headaches. Your child may become constipated or have oily stools
and toileting accidents. The medicine also affects the heart. It could speed up the heart rate and
cause your child to become jittery. Also, your child may not be able to drink anything with a large
amount of caffeine, such as cola or tea. Some children get rashes from the medicine.
Medication (Metformin/Glucophage)
The doctor gives your child medicine to keep him/her from getting diabetes. The medicine
will help to keep your child’s blood sugar at a healthy level. By doing this, your child’s body can
use the food better and is less likely to get diabetes. You give your child a pill every evening at
supper. You also bring your child back to the doctor for a check-up about every three months.
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The medicine can cause your child to have mild stomachaches and feel like throwing up. Your
child may not feel like eating and could lose weight. Your child may have diarrhea. Your child
also may complain about a metallic taste in the mouth. Some children have trouble breathing, are
extra tired, get dizzy, or throw up.
Dietary Change Alone
You change your child’s regular eating habits to keep him/her from getting diabetes. At
the beginning of treatment, you and your child attend a 1-hour class every week for 10 weeks.
The class teaches how to eat properly at home and when eating out. You feed your child healthy
foods and snacks, such as fruits and vegetables. You learn to not reward your child with food.
You encourage your child to choose fruits, vegetables, and lean meats (like chicken) at school.
You praise your child when he/she chooses the healthy foods. You reward your child with
something he/she enjoys when he/she eats less junk food and more fruits and vegetables at home
or at school. You also reward your child when he/she eats smaller amounts of food during meals
and at snack-time. It might be hard to change the foods that your child eats. Your child might not
like some of the foods. It might be difficult to make your child eat different foods than the rest of
the family. It might be hard to keep track of what your child eats when he/she is not at home.
Family Lifestyle Change
You change your family’s lifestyle by improving the eating habits and fitness of the whole
family to keep your child from getting diabetes. At the beginning of treatment, your family
attends a 1-hour class every week for 10 weeks. You learn about healthy eating and exercise.
The family learns about what foods to eat and what foods not to eat. You learn to cook healthy
meals with vegetables, fruits, and chicken or fish (not fried foods). You learn to be active 3-4
times a week, such as riding a bicycle, walking quickly, or playing sports, instead of watching TV
or just sitting around. You learn to reward your family by letting them do things they enjoy, only
when they eat healthy and exercise. The goal is to make these things a part of everyday life, such
as taking the stairs instead of the elevator. This treatment takes a long time to learn and a lot of
effort to make a part of everyday life. Your whole family must take part, and it may be hard to
keep track of your family during the day.
Gene Therapy
You choose gene therapy for your child to keep him/her from getting diabetes. Genes are
in every cell of our bodies. They cause height, hair color, and eye color. They also can cause us
to be more likely to get certain illnesses, like diabetes. Gene therapy is something that doctors
can do to change the genes in our cells. The goal of gene therapy is to give your child healthy
genes that will make your child less likely to get diabetes. To do this, the doctor injects healthy
genes into your child’s body by giving him/her a shot. The body makes copies of the new healthy
genes. This means that the genes that would have caused diabetes are now gone and replaced
with healthy genes. Getting a shot is painful to some children. There is a small chance that your
child could reject the new healthy genes, which could cause severe health risks. Your child also
could have children who carry these new genes that may or may not work for them.
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Appendix I
Treatment Evaluation Inventory – Short Form
Please complete the items listed below by placing a checkmark on the line next to each question
that best indicates how you feel about the treatment. Please read the items very carefully because
a checkmark accidentally placed on one space rather than another may not represent the meaning
you intended.
Strongly

1. I find this approach to be an acceptable
way of dealing with the child’s weight.
(diabetes/problem)

Disagree Disagree Neutral

Agree

Strongly

Agree_

____

____

____

____

____

____

____

____

____

____

3. I believe that it would be acceptable to
use this approach without children’s
consent.

____

____

____

____

____

4. I like the procedure used in this approach.

____

____

____

____

____

5. I believe this approach is likely to be
effective.

____

____

____

____

____

6. I believe the child will experience
discomfort during the approach.

____

____

____

____

____

7. I believe this approach is likely to result
in permanent improvement.

____

____

____

____

____

8. I believe it would be acceptable to use this
approach with individuals who cannot
choose treatments for themselves.

____

____

____

____

____

9. Overall, I have a positive reaction to this
approach.

____

____

____

____

____

2. I would be willing to use this procedure
if I had to change the child’s weight.
(diabetes/problem)
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